US20110039332A1 - Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue - Google Patents

Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue Download PDF

Info

Publication number
US20110039332A1
US20110039332A1 US12/663,840 US66384007A US2011039332A1 US 20110039332 A1 US20110039332 A1 US 20110039332A1 US 66384007 A US66384007 A US 66384007A US 2011039332 A1 US2011039332 A1 US 2011039332A1
Authority
US
United States
Prior art keywords
human
stem cell
cells
pluripotent stem
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/663,840
Other languages
English (en)
Inventor
Kazuhiro Sakurada
Hldeki Masaki
Tetsuya Ishikawa
Shunichi Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to IZUMI BIO, INC. reassignment IZUMI BIO, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Publication of US20110039332A1 publication Critical patent/US20110039332A1/en
Assigned to KYOTO UNIVERSITY reassignment KYOTO UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IPIERIAN, INC.
Assigned to BAYER YAKUHIN, LTD. reassignment BAYER YAKUHIN, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ISHIKAWA, TETSUYA, MASAKI, HIDEKI, SAKURADA, KAZUHIRO, TAKAHASHI, SHUNICHI
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAYER YAKUHIN, LTD.
Assigned to IPIERIAN, INC. reassignment IPIERIAN, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: IZUMI BIO, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Definitions

  • the present invention relates to human pluripotent stem cells induced from stem cells present in a human postnatal tissue and its inducing method.
  • diseases associated with tissue degeneration and tissue injury are rapidly increasing. Said diseases include cerebral infarction, myocardial infarction and renal failure that develop in an age-dependent manner due to the metabolic syndrome, Alzheimer's disease, Parkinson's disease and osteoporosis that are induced by age-related internal changes of the tissue, and the like.
  • Type I diabetes, multiple sclerosis and rheumatoid arthritis induced by autoimmune diseases as well as burns and spinal injuries induced by wounds are also diseases characterized by tissue degeneration and tissue injury. As methods of treating such diseases resulting from tissue degeneration and injury, various regenerative medical techniques are being developed now.
  • Regenerative medicine is roughly divided into two methods: the induced regeneration method in which endogenous stem cells in patients are activated with a drug etc., and the cell replacement therapy in which stem cells or somatic cells induced from stem cells or tissues are transplanted.
  • the induced regeneration method does not work well due to reduced function of stem cells from the patient per se, and thus the development of the cell replacement therapy is imperative.
  • a large amount of stem cells or somatic cells induced from stem cells generally need to be prepared as materials for transplantation.
  • stem cells that can differentiate into various tissues and that can self-replicate for a long time are indispensable for the development of a cell replacement therapy.
  • stem cells from cells derived from a human postnatal tissue, said stem cells having properties close to that of ES cells and comprising the genome of the patient per se thereby circumventing immunological rejection of transplanted cells.
  • human pluripotent stem cells can be induced by introducing three genes of Oct3/4, Sox2 and Klf4 or three genes of Oct3/4, Sox2 and Klf4 plus the c-Myc gene or a histone deacetylase (HDAC) inhibitor into undifferentiated stem cells present in a human postnatal tissue in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation.
  • HDAC histone deacetylase
  • Human postnatal tissues are preferably tissues immediately after birth (various tissues of neonates), umbilical cord tissues (the umbilical cord, cord blood), the amnion, the placenta etc., and more preferably various neonatal tissues and umbilical cord tissues.
  • Post-natal tissues include tissues of various timings during the period from the birth of an individual to its death.
  • the undifferentiated stem cells refer to stem cells in which at least four genes of Nanog, Oct3/4, Sox2 and Tert have not undergone epigenetic modification by heterochromatin formation due to DNA methylation or histone modification, among the primordial cells in the tissue of somatic stem cells established in vitro, such as mesenchymal stem cells (Science, 1999, April 2; 284 (5411): 143-7) and MAPCs (multipotent adult progenitor cells) (Stem Cell Rev. 2005; 1(1): 53-9), and MIAMI (marrow-isolated adult multilineage inducible) cells (J. Cell Sci. 2004 Jun. 15; 117 (Pt 14): 2971-81).
  • ES cell-like pluripotent stem cells refer to cells having an in vitro long-term self-renewal ability and the pluripotency of differentiating into three germ layers, and said pluripotent stem cells may form teratoma when transplanted into a test animal such as mouse.
  • the present invention is thought to provide a useful technique for the cell replacement therapy for the treatment of diseases resulting from tissue degeneration or injury.
  • cells that can be transformed into ES cell-like pluripotent stem cells by introducing four genes of Oct3/4, Sox2, Klf4 and c-Myc are undifferentiated stem cells in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation;
  • ES cell-like pluripotent stem cells can be induced from undifferentiated stem cells in which the Tert, Nanog, Oct3/4 and Sox2 genes have not undergone epigenetic inactivation present in postnatal tissues, and thus, it is expected that, in the case of humans as well, by adding a histone deacetylase inhibitor in stead of the c-Myc gene to undifferentiated stem cells in which the Tert, Nanog, Oct3/4 and Sox2 genes have not undergone epigenetic inactivation, they could be transformed into ES cell-like pluripotent stem cells.
  • the present invention provides the following (1) to (35):
  • a human pluripotent stem cell having an in vitro long-term self-renewal ability and the pluripotency of differentiating into ectoderm, mesoderm and endoderm, that was induced from an undifferentiated stem cell present in a human postnatal tissue in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation.
  • the human pluripotent stem cell according to the above (1) induced from an undifferentiated stem cell present in a human postnatal tissue, wherein said undifferentiated stem cell present in the human postnatal tissue was subjected to a primary culture or a second subculture, or a subculture in a low serum concentration.
  • the human pluripotent stem cell according to the above (1) induced by combining the forced expression of each of three genes of Oct3/4, Sox2 and Klf4 and a histone deacetylase inhibitor treatment in an undifferentiated stem cell present in a human postnatal tissue, wherein said undifferentiated stem cell present in the human postnatal tissue was subjected to a primary culture or a second subculture or to a subculture in a low serum concentration.
  • the human pluripotent stem cell according to the above (1) induced by combining the forced expression of each of three genes of Oct3/4, Sox2 and Klf4 and a MS-275 treatment in an undifferentiated stem cell present in a human postnatal tissue, wherein said undifferentiated stem cell present in the human postnatal tissue was subjected to a primary culture or a second subculture or to a subculture in a low serum concentration.
  • the human pluripotent stem cell according to any one of the above (1) to (12) wherein said human pluripotent stem cell comes to have teratoma-forming potential when it is transplanted into a test animal.
  • the human pluripotent stem cell according to any one of the above (1) to (13) wherein said human postnatal tissue is a tissue immediately after birth and is a tissue derived from a neonatal tissue or an umbilical cord tissue.
  • the human pluripotent stem cell according to any one of the above (1) to (13) wherein said human postnatal tissue is a tissue immediately after birth and is a tissue derived from a neonatal skin or a blood vessel derived from the umbilical cord.
  • the undifferentiated stem cell present in a human postnatal tissue according to any one of the above (18) to (21), wherein said human postnatal tissue is a tissue immediately after birth and is a tissue derived from a neonatal tissue or an umbilical cord tissue.
  • the undifferentiated stem cell present in a human postnatal tissue according to any one of the above (18) to (21), wherein said human postnatal tissue is a tissue immediately after birth and is a tissue derived from a neonatal skin or a blood vessel of the umbilical cord.
  • a method of inducing a human pluripotent stem cell wherein an undifferentiated stem cell present in a human postnatal tissue, in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation, is subjected to a primary culture or a second subculture or to a third or fourth subculture in a low serum concentration at 0 to 5%, and then each of three genes of Oct3/4, Sox2 and Klf4 is subjected to forced expression.
  • the undifferentiated stem cells of the present invention present in a human postnatal tissue refer to stem cells that have not undergone epigenetic modification by heterochromatin formation due to DNA methylation or histone modification of at least four genes of Nanog, Oct3/4, Sox2 and Tert among the primordial cells in the tissue of various somatic stem cells established in vitro, such as mesenchymal stem cells, MAPCs and MIAMI cells.
  • stem cells that have not undergone epigenetic modification by heterochromatin formation due to DNA methylation or histone modification of at least four genes of Nanog, Oct3/4, Sox2 and Tert among the primordial cells in the tissue of various somatic stem cells established in vitro, such as mesenchymal stem cells, MAPCs and MIAMI cells.
  • Mesenchymal stem cells refer to those cells having the potential of differentiating into mesenchymal cells (bone, cartilage, fat) among the cells (interstitial cells) obtained as nonhematopoietic cells that are adherent to a plastic culture tray when tissues of bone marrow, fat, muscle, skin etc. are cultured in a culture medium containing a high-concentration serum (5% or more).
  • mesenchymal stem cells are the cells obtained by the above culturing, and thus their properties are different from those of the undifferentiated cells (stem cells in which at least four genes of Nanog, Oct3/4, Sox2 and Tert have not undergone epigenetic modification by heterochromatin formation due to DNA methylation or histone modification, among the primordial cells in the tissue of somatic stem cells established in vitro, such as mesenchymal stem cells, MAPCs and MIAMI cells) immediately after isolation from human postnatal tissues.
  • the undifferentiated cells stem cells in which at least four genes of Nanog, Oct3/4, Sox2 and Tert have not undergone epigenetic modification by heterochromatin formation due to DNA methylation or histone modification, among the primordial cells in the tissue of somatic stem cells established in vitro, such as mesenchymal stem cells, MAPCs and MIAMI cells
  • each tissue at various timings during the period from the birth of an individual to its death (bone marrow fluid, muscle, adipose tissue, peripheral blood, skin, skeletal muscle etc.) and tissues concomitant to birth such as cord tissues (umbilical cord, cord blood), the amnion, the placenta and the like, preferably there can be mentioned tissues (bone marrow fluid, muscle, adipose tissue, peripheral blood, skin, skeletal muscle etc.) immediately after birth such as various neonatal tissues, and more preferably there can be mentioned various neonatal tissues such as neonatal skin and cord tissues (umbilical cord, cord blood) such as tissues derived from cord-derived blood vessels.
  • Undifferentiated stem cells present in the human postnatal tissues of the present invention can be cultured for a certain period from a primary culture in a culture medium containing or not containing a low concentration serum (preferably 2% or less) and to which cell growth factors (PDGF, EGF, FGF-2 etc.) have been added or not added, and have properties different from those of mesenchymal stem cells that are characterized by a long time culturing in the serum (concentrations exceeding 5%).
  • a low concentration serum preferably 2% or less
  • cell growth factors PDGF, EGF, FGF-2 etc.
  • FGF-2 As the above cell growth factors, there can be mentioned FGF-2, PDGF, EGF, IGF, insulin, TGFb-1, activin A, noggin, BDNF, NGF, NT-1, NT-2, NT-3 and the like, and the addition of FGF-2 alone or the addition of both PDGF and EGF is preferred.
  • FGF-2 stands for basic fibroblast growth factor
  • PDGF platelet-derived growth factor
  • EGF epidermal growth factor
  • IGF insulin-like growth factor
  • TGF ⁇ -1 stands for transforming growth factor ⁇ -1
  • BDNF brain-derived neurotrophic factor
  • NGF nerve growth factor
  • NT-1 stands for neurotrophin-1
  • NT-2 stands for neurotrophin-2
  • NT-3 stands for neurotrophin-3.
  • the above primary culture represents immediately after isolation from a human, the primary culture cells subcultured once represent the second subculture, the primary culture cells subcultured twice represent the third subculture, and the primary culture cells subcultured three times represent the fourth subculture.
  • Culturing for a certain period from the above primary culture generally means from the primary culture to the fourth subculture, preferably from the primary culture to the second subculture.
  • Human pluripotent stem cells induced from undifferentiated stem cells present in a human postnatal tissue in which the Tert, Nanog, Oct3/4 and Sox2 genes have not undergone epigenetic inactivation represent stem cells that have a long-term self-renewal ability under the condition for culturing human ES cells and an in vitro pluripotency of differentiating into ectoderm, mesoderm and endoderm under the condition for inducing in vitro differentiation of human ES cells, and the above human pluripotent stem cells may further have a potential of differentiating into primordial germ cells under the condition for inducing in vitro differentiation of human ES cells.
  • human pluripotent stem cells of the present invention induced from undifferentiated stem cells present in a human postnatal tissue in which the Tert, Nanog, Oct3/4 and Sox2 genes have not undergone epigenetic inactivation may be stem cells that have an ability of forming teratoma when transplanted into a test animal such as mouse.
  • the low concentration serum encompassed by the present invention is generally serum at a concentration of 5% or less, preferably serum at a concentration of 2% or less, and the low density as used herein is a concentration of about 10% or less.
  • the following method may be mentioned.
  • the cells are fixed in a 10% formaldehyde solution at room temperature for 2 to 5 minutes, washed with a phosphate buffer etc., a solution of nitroblue tetrazolium chloride/5-bromo-4-chloro-3′-indolyl phosphate p-toluidine salt (hereinafter referred to as the NBT/BCIP solution), a chromogenic substrate of alkaline phosphatase, is added, and reacted at room temperature for 20-30 minutes.
  • NBT/BCIP solution a solution of nitroblue tetrazolium chloride/5-bromo-4-chloro-3′-indolyl phosphate p-toluidine salt
  • the human pluripotent stem cells were expressed cell surface antigens SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, CD9, CD24, and CD90, and ES cell marker genes Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1.
  • the promoter regions of Nanog and Oct3/4 in the human pluripotent stem cells were demethylated compared to the parental fibroblasts.
  • the human pluripotent stem cells carries at least a single copy of Oct3/4, Sox2, Klf4, and c-Myc transgene.
  • the induced human pluripotent stem cells and the parental cells had almost the same SNP genotype each other, and HLA type of the induced human pluripotent stem cell was completely identical to that of the parental cell (undifferentiated stem cell present in a human postnatal tissue).
  • a histone deacetylase inhibitor and MS-275 and a treatment method using them are as describe later:
  • the method of forced expression as used herein comprises a method for external expression in which a gene is expressed by introducing it with a vector etc. and a method for internal expression in which internal expression is promoted by the stimulation of a drug etc.
  • forced expression as used herein also encompasses a method in which the genes of Oct3/4, Sox2, Klf4 and c-Myc are extracellularly expressed, and then the proteins produced of Oct3/4, Sox2, Klf4 and c-Myc are introduced directly into the cell using a method for introducing protein.
  • the method for introducing protein there can be mentioned in case of a method that employs a commercially available carrier reagent (Chariot, BioPorter, GenomONE), the PTD (protein transduction domain) fusion protein method, the electroporation method, the microinjection method and the like.
  • the external expression method in which each gene of Oct3/4, Sox2, Klf4 and c-Myc is introduced into a vector etc. for forced expression is as follows:
  • the donor In order to harvest a bone marrow fluid from human bone marrow, the donor is given a general anesthetic, then placed on a prone position, and from the posterior border of the ilium, a needle called the bone marrow collection needle is stuck directly into the skin to lead the needle through the iliac surface to the bone marrow, and the liquid of the bone marrow is aspirated with a syringe.
  • the mononuclear cell fraction separated by density centrifugation is collected.
  • the collected cell fraction as crude purified cells containing the undifferentiated stem cells, is cultured according to the method described in 6, and used for the induction of human pluripotent stem cells of the present invention.
  • a skin tissue containing the epidermis and the dermis is harvested. This skin tissue is immersed in 0.6% trypsin (manufactured by Invitrogen)/DMEM (Dulbecco's Modified Eagle's Medium)/F-12 (manufactured by Invitrogen)/1% antibiotics, antimycotics (manufactured by Invitrogen) with the inner side of the skin facing downward, and treated at 37° C. for 30 minutes.
  • the skin tissue is finely cut into about 1 mm 2 sections using scissors, which are then centrifuged at 1200 rpm and room temperature for 10 minutes. The supernatant is removed, and to the tissue precipitate is added 25 ml of 0.1% trypsin/DMEM/F-12/1% antibiotics, antimycotics, and stirred using a stirrer at 37° C. and 200-300 rpm for 40 minutes.
  • fetal bovine serum (manufactured by JRH) is added, and filtered sequentially with gauze (Type I manufactured by PIP), a 100 ⁇ m nylon filter (manufactured by FALCON) and a 40 ⁇ m nylon filter (manufactured by FALCON).
  • gauze Type I manufactured by PIP
  • DMEM/F-12/1% antibiotics, antimycotics is added to wash the precipitate, and then centrifuged at 1200 rpm and room temperature for 10 minutes.
  • the cell faction thus obtained may be cultured according to the method described in 6. below as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent stem cells of the present invention.
  • a connective tissue containing muscle such as a lateral head of biceps brachii muscle and a sartorius muscle of the leg is cut and the muscle is excised, it is sutured.
  • the whole muscle obtained is minced with scissors or a scalpel, and then suspended in DMEM (high glucose) containing 0.06% collagenase type IA (manufactured by SIGMA) and 10% FBS, and incubated at 37° C. for 2 hours.
  • the cell fraction obtained may be cultured according to the method described in 6. below as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent stem cells of the present invention.
  • adipose tissue for use in the present invention may be isolated by various methods known to a person skilled in the art. For example, such a method is described in U.S. Pat. No. 6,153,432, which is incorporated herein in its entirety.
  • a preferred source of adipose tissue is omental adipose tissue. In humans, adipose cells are typically isolated by fat aspiration.
  • adipose tissue is treated with 0.01% to 0.5%, preferably 0.04% to 0.2%, and most preferably about 0.1% collagenase, 0.01% to 0.5%, preferably 0.04%, and most preferably about 0.2% trypsin and/or 0.5 ng/ml to 10 ng/ml dispase, or an effective amount of hyaluronidase or DNase (DNA digesting enzyme), and about 0.01 to about 2.0 mM, preferably about 0.1 to about 1.0 mM, most preferably 0.53 mM concentration of ethylenediaminetetraacetic acid (EDTA) at 25 to 50° C., preferably 33 to 40° C., and most preferably 37° C. for 10 minutes to 3 hours, preferably 30 minutes to 1 hour, and most preferably 45 minutes.
  • EDTA ethylenediaminetetraacetic acid
  • Cells are passed through nylon or a cheese cloth mesh filter of 20 microns to 800 microns, more preferably 40 microns to 400 microns, and most preferably 70 microns. Then the cells in the culture medium are subjected to differential centrifugation directly or using Ficoll or Percoll or another particle gradient. The cells are centrifuged at 100 to 3000 ⁇ g, more preferably 200 to 1500 ⁇ g, most preferably 500 ⁇ g for 1 minute to 1 hours, more preferably 2 to 15 minutes and most preferably 5 minutes, at 4 to 50° C., preferably 20 to 40° C. and more preferably about 25° C.
  • the adipose tissue-derived cell fraction thus obtained may be cultured according to the method described in 6. below as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent stem cells of the present invention.
  • a RPMI 1640 medium manufactured by Invitrogen
  • an essential medium for culturing peripheral blood stem cells containing 10% fetal bovine serum (manufactured by JRH Biosciences), 100 ⁇ g/ml streptomycin and 100 units/ml penicillin (manufactured by Invitrogen), and after washing twice, the cells are recovered.
  • the recovered cells are suspended again in the essential medium for culturing peripheral blood stem cells, which is then plated in a 100 mm plastic culture dish at 1 ⁇ 10 7 cells/dish, and incubated in a 37° C. incubator under a condition of 8% CO 2 . After 10 hours, suspended cells are removed and the attached cells are only harvested by pipetting.
  • peripheral blood-derived or cord blood-derived adherent cell fraction thus obtained may be cultured according to the method described in 6. below as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent stem cells of the present invention.
  • Examples of culture media useful in culturing the undifferentiated stem cells of the present invention present in a human postnatal tissue include the ES medium [40% Dulbecco's Modified Eagle's Medium (DMEM), 40% F12 medium, 2 mM L-glutamine, 1% non-essential amino acids, 0.1 mM ⁇ -mercaptoethanol (the above are manufactured by SIGMA), 20% Knockout Serum Replacement (manufactured by Invitrogen), 10 ⁇ g/ml gentamycin (manufactured by Invitrogen)] (hereinafter referred to as the ES medium), the MAPC medium [60% Dulbecco's Modified Eagle's Medium-low glucose (manufactured by Invitrogen), 40% MCDB 201 (manufactured by Invitrogen), 1 ⁇ ITS medium supplement (manufactured by SIGMA), 1 ⁇ linolenic acid albumin (manufactured by SIGMA), 1 nM dexa
  • growth factors As “growth factors, cytokines, hormones” to be added to the above culture medium, there can be mentioned FGF-2, PDGF, EGF, IGF, insulin, TGFb-1, activin A, Noggin, BDNF, NGF, NT-1, NT-2, NT-3 and the like.
  • the cell fraction obtained by the above methods 1. to 5. is cultured in a medium containing the above additives for about 1 to 12 days at a low density of about 10 3 cells/cm 2 to 10 4 cells/cm 2 .
  • retrovirus vectors including lentivirus vectors
  • adenovirus vectors are used to introduce a mouse-derived cationic amino acid transporter (mCAT) gene
  • mCAT mouse-derived cationic amino acid transporter
  • virus vector plasmids there can be mentioned pMXs, pMXs-IB, pMXs-puro, pMXs-neo (pMXs-IB is a vector carrying the blasticidin-resistant gene in stead of the puromycin-resistant gene of pMXs-puro) [Experimental Hematology, 2003, 31 (11): 1007-14], MFG [Proc. Natl. Acad. Sci. U.S.A.
  • any cells may be used that can supply a lacking protein of a recombinant virus vector plasmid deficient in at least one gene encoding a protein required for virus packaging.
  • HEK-293 cells derived from human kidney, packaging cells based on a mouse fibroblast NIH3T3, and the like.
  • retrovirus-derived proteins such as gag, pol, and env in the case of retrovirus vectors
  • HIV-derived proteins such as gag, pol, env, vpr, vpu, vif, tat, rev, and nef in the case of lentivirus vectors
  • adenovirus-derived proteins such as E1A and E1B in the case of adenovirus vectors.
  • recombinant virus vectors By introducing any of the above recombinant virus vector plasmid into the above packaging cells, recombinant virus vectors can be produced.
  • various gene introduction methods are known including, but not limited to, the calcium phosphate method [Kokai (Japanese Unexamined Patent Publication) No. 2-227075], the lipofection method [Proc. Natl. Acad. Sci. U.S.A. 84: 7413 (1987)], the electroporation method and the like, and any suitable method may be used from the known gene introduction methods.
  • histone acetylase inhibitors there can be mentioned those described in the following A to E, and among them MS-275 is preferred.
  • Trichostatin A and its analogs for example: trichostatin A (TSA); and trichostatin C (Koghe et al. 1998, Biochem. Pharmacol. 56: 1359-1364).
  • Peptides for example: oxamflatin [(2E)-5-[3-[(phenylsulfonyl)aminophenyl]-pent-2-ene-4-inohydroxamic acid (Kim et al., Oncogene 18: 2461-2470 (1999)); Trapoxin A (cyclo-(L-phenylalanyl-L-phenylalanyl-D-pipecolinyl-L-2-amino-8-oxo-9,10-epoxy-decanoyl (Kijima et al., J. Biol. Chem.
  • FR901228 depsipeptide
  • FR225497 cyclic tetrapeptide
  • apicidin cyclic tetrapeptide [cyclo-(N—O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl)] (Darkin-Rattray et al., Proc. Natl.
  • Hybrid polar compounds based on hydroxamic acid, for example: salicyl hydroxamic acid (SBHA) (Andrews et al., International J. Parasitology 30: 761-8 (2000)); suberoylanilide hydroxamic acid (SAHA) (Richon et al., Proc. Natl. Acad. Sci. U.S.A. 95: 3003-7 (1998)); azelaic bishydroxamic acid (ABHA) (Andrews et al., supra); azelaic-1-hydroxamate-9-anilide (AAHA) (Qiu et al., Mol. Biol.
  • SBHA salicyl hydroxamic acid
  • SAHA suberoylanilide hydroxamic acid
  • SAHA suberoylanilide hydroxamic acid
  • SAHA suberoylanilide hydroxamic acid
  • ABHA azelaic bishydroxamic acid
  • AAHA a
  • M-carboxy cinnamic acid bishydroxamide (CBHA) (Ricon et al., supra); 6-(3-chlorophenylureido) carpoic hydroxamic acid, 3-Cl-UCHA) (Richon et al., supra); MW2796 (Andrews et al., supra); and MW2996 (Andrews et al., supra).
  • SCFA Short chain fatty acid
  • valproic acid valerate (McBain et al., supra); 4-phenyl butyric acid (4-PBA) (Lea and Tulsyan, Anticancer RESearch 15: 879-3 (1995)); phenyl butyric acid (PB) (Wang et al., Cancer RESearch 59: 2766-99 (1999)); propinate (McBain et al., supra); butylamide (Lea and Tulsyan, supra); isobutylamide (Lea and Tulsyan, supra); phenyl acetate (Lea and Tulsyan, supra); 3-bromopropionate (Lea and Tulsyan, supra); tributyrin (Guan et al., Cancer RESearch 60: 749-55 (2000)); arginine butyrate; isobutyl amide; and valproate.
  • 4-PBA 4-phenyl butyric acid
  • PB phenyl butyric
  • Benzamide derivatives for example: MS-275 [N-(2-aminophenyl)-4-[N-(pyridine-3-yl-methoxycarbonyl)aminomethyl]benzamide] (Saito et al., Proc. Natl. Acad. Sci. U.S.A. 96: 4592-7 (1999)); and a 3′-amino derivative of MS-275 (Saito et al., supra); and CI-994.
  • a histone deacetylase inhibitor treatment may be carried out, for example, as follows:
  • the concentration of the histone deacetylase inhibitor used depends on a particular inhibitor, but is preferably 0.001 nM to about 10 mM, and more preferably about 0.01 nM to about 1000 nM.
  • the effective amount or the dosage of a histone deacetylase inhibitor is defined as the amount of the histone deacetylase inhibitor that does not significantly decrease the survival rate of cells, specifically undifferentiated stem cells. Cells are exposed for 1 to 5 days or 1 to 3 days. The exposure period may be less than one day. In a specific embodiment, cells are cultured for about 1 to 5 days, and then exposed to an effective amount of a histone deacetylase inhibitor. However, the histone deacetylase inhibitor may be added at the start of culturing. Within such a time frame, a gene-carrying vehicle such as a vector containing a nucleic acid encoding three genes (Oct3/4, Sox2 and Klf4) is introduced into cultured cells by a known method.
  • Examples of culture media useful for culturing human pluripotent stem cells induced from undifferentiated stem cells present in a human postnatal tissue of the present invention include, but not limited to, the ES medium, and a culture medium suitable for culturing human ES cells such as MEF-conditioned ES medium (hereinafter referred to as the MEF-conditioned ES medium) which is a supernatant obtained by adding 10 ng/ml FGF-2 to the ES medium and then mouse embryonic fibroblasts (hereinafter referred to as MEF) were added thereto and cultured for 24 hours to obtain the supernatant.
  • MEF-conditioned ES medium MEF-conditioned ES medium
  • MEF-conditioned ES medium mouse embryonic fibroblasts
  • growth factors As “growth factors, cytokines, hormones” to be added to the above culture media, there can be mentioned ingredients involved in the growth and maintenance of human ES cells including FGF-2, TGFb-1, activin A, Nanoggin, BDNF, NGF, NT-1, NT-2, NT-3 and the like.
  • Y-27632 Calbiochem; water soluble
  • Fasudil HA1077: Calbiochem
  • Rho associated kinase an inhibitor of Rho associated kinase (Rho associated coiled coil-containing protein kinase) is also useful for culturing the human pluripotent stem cells of the present invention.
  • the cells are subcultured every 5 to 7 days in a culture medium containing the above additives on a MEF-covered plastic culture dish or a matrigel-coated plastic culture dish to 1:3 to 1:6 or plated at 10 3 cells/cm 2 to 3 ⁇ 10 4 cells/cm 2 .
  • undifferentiated stem cells present in a human postnatal tissue are detected at high rates in young individuals, preferred undifferentiated stem cells for the cell bank are cord blood, the umbilical cord, the placenta, skin obtained from neonates and the like. Even in adults, undifferentiated stem cells for the cell bank may be harvested from the bone marrow, adipose tissue, peripheral blood, skin and the like depending on the physical status of the donor.
  • the undifferentiated stem cells of the present invention obtained from each donor may be stored frozen as they are, or may be transformed into human pluripotent stem cells according to the above-mentioned method of the present invention prior to storing frozen.
  • the undifferentiated stem cells of the present invention or the human pluripotent stem cells of the present invention thus stored may be used for the treatment of the donor per se or of immunohistologically compatible recipients as well.
  • the human pluripotent stem cells of the present invention In treatment, depending on the amount of cell replacement required for the treatment of the subject disease, the human pluripotent stem cells of the present invention must be subcultured according to the method of the above 8.
  • the required number of the human pluripotent stem cells of the present invention obtained by subculturing can be used for the treatment of various diseases by a method described below.
  • Diseases of the central nervous system using the human pluripotent stem cells of the present invention include Parkinson's disease, Alzheimer's disease, multiple sclerosis, cerebral infarction, spinal injury and the like.
  • Parkinson's disease a therapeutic method is possible in which human pluripotent stem cells are differentiated into dopamine-acting neurons and then transplanted into the striate body of the patient with Parkinson's disease. Differentiation into dopamine-acting neurons can be effected by coculturing the PA6 cell which is a mouse stromal cell line and the human pluripotent stem cells of the present invention under a serum-free condition.
  • the human pluripotent stem cells of the present invention are induced to differentiate into neural stem cells followed by transplantation into the injured site is effective.
  • the human pluripotent stem cells of the present invention are cultured in suspension to form an embryoid body, and the embryoid body obtained is cultured in a serum-free medium containing FGF-2 for use in the culture of neural stem cells.
  • the human pluripotent stem cells of the present invention are cocultured with the PA6 cell which is a mouse stromal cell line, and then cultured in a serum-free medium containing FGF-2 for use in the culture of neural stem cells.
  • the human pluripotent stem cells of the present invention are transferred to a serum-free medium containing FGF-2 to directly induce differentiation.
  • treatment can be effected by further inducing the differentiation of neural stem cells induced from the human pluripotent stem cells of the present invention into oligodendrocytes or progenitors of oligodendrocytes, which are then transplanted to the injured site.
  • oligodendrocytes or progenitors of oligodendrocytes from neural stem cells induced from the human pluripotent stem cells of the present invention
  • a method of culturing said neural stem cells in the presence of a fusion protein between a soluble interleukin-6 receptor and interleukin-6 there can be mentioned a method of culturing said neural stem cells in the presence of a fusion protein between a soluble interleukin-6 receptor and interleukin-6.
  • the human pluripotent stem cells of the present invention can be used for the treatment of hepatic diseases such as hepatitis, cirrhosis and liver failure.
  • the human pluripotent stem cells of the present invention are preferably differentiated to hepatic cells or hepatic stem cells, and then are transplanted.
  • Hepatic cells or hepatic stem cells may be obtained by culturing the human pluripotent stem cells of the present invention in the presence of activin A for 5 days, and then culturing in the presence of the hepatocyte growth factor (HGF) for about a week to obtain hepatic cell or hepatic stem cells.
  • HGF hepatocyte growth factor
  • the human pluripotent stem cells of the present invention can be used for the treatment of pancreatic diseases such as type I diabetes mellitus.
  • pancreatic diseases such as type I diabetes mellitus.
  • the human pluripotent stem cells of the present invention are preferably differentiated to pancreatic beta cells, and then are transplanted to the pancreas.
  • the human pluripotent stem cells of the present invention can be differentiated to pancreatic beta cells in following six steps of culturing: (1) culturing in the presence of a serum-free medium, activin A and Wnt protein for 1 to 2 days; (2) culturing in the presence of 0.2% FBS and activin A for 1 to 2 days; (3) culturing in the presence of 2% FBS, FGF-10 and KAAD-cyclopamine (keto-N-aminoethylaminocaproyl dihydrocinnamoylcyclopamine) for 2 to 4 days; (4) culturing in the presence of 1% B27 (manufactured by Invitrogen), FGF-10, KAAD-cyclopamine and retinoic acid for 2 to 4 days; (5) culturing in the presence of 1% B27, gamma secretase inhibitor and extendin-4 for 2 to 3 days; (6) culturing in the presence of 1% B27, extendin-4, IGF
  • the human pluripotent stem cells of the present invention can be used for the treatment of heart failure associated with ischemic heart diseases.
  • the human pluripotent stem cells of the present invention are preferably differentiated into cardiac muscle cells prior to transplanting to the injured site.
  • cardiac muscle cells can be obtained from the human pluripotent stem cells of the present invention in about 2 weeks after forming the embryoid body.
  • the present invention provides for the first time human pluripotent stem cells induced from undifferentiated stem cells present in a human postnatal tissue and having an in vitro long-term self-renewal ability and the pluripotency of differentiating into ectoderm, mesoderm and endoderm, and further said human pluripotent stem cells may have a potential of differentiating into primordial germ cells.
  • Cells in a tissue that was lost in diseases etc. can be supplied by inducing human pluripotent cells from the undifferentiated stem cells harvested from a patient by using the induction method of the present invention, followed by inducing to differenciate into a necessary cell depending on diseases and then transplanting the cells to the patient.
  • the undifferentiated stem cells of the present invention present in a human postnatal tissue can be used to search drugs that promote the induction from said undifferentiated stem cells to human pluripotent stem cells by using markers such as Tert, Nanog, Sox2, Oct3/4 and alkaline phosphatase that direct the induction to human pluripotent stem cells. Said drugs can be used in stead of gene introduction and can enhance the induction efficiency of human pluripotent stem cells.
  • FIG. 1 Four genes of Oct3/4, Sox2, Klf4 and c-Myc were introduced into cells established under a low serum condition from mononuclear cells derived from a human adult bone marrow, and RNA was extracted from the colonies obtained, and the amount expressed of the human Nanog and human Tert genes was demonstrated by quantitative PCR. Fibroblasts and mesenchymal stem cells in which the four genes were not introduced were used as the control in the experiment. The amount expressed of the gene was expressed by a relative value in which the amount expressed was normalized by the amount expressed of the human HPRT gene, and by setting as one the amount expressed of the gene in alkaline phosphatase-positive colonies induced from a neonatal skin fibroblast established by example 6. It was confirmed that the expression of Nanog and Tert was significantly high in colonies in which four genes were introduced and which were positive for alkaline phosphatase.
  • FIG. 2 Four genes of Oct3/4, Sox2, Klf4 and c-Myc were introduced into the primary culture fibroblasts derived from a neonatal skin, RNA was extracted from the colonies obtained, and the amount expressed of the human Nanog and human Tert genes was demonstrated by quantitative PCR. Its parental fibroblasts and mesenchymal stem cells in which four genes were not introduced were used as the control in the experiment. The amount expressed of genes was normalized by the amount expressed of the human HPRT gene, and further was expressed by a relative value by setting as one the amount expressed of the gene in alkaline phosphatase-positive colonies induced from a neonatal skin fibroblast established by example 6. It was confirmed that the expression of Nanog and Tert was significantly high in colonies in which four genes were introduced and which were positive for alkaline phosphatase.
  • FIG. 3 After three gene introduction and treatment with MS-275 (0.1 or 1.0 ⁇ M), a histone deacetylase (HDAC) inhibitor by using cells derived from a mouse bone marrow established under a low serum condition, RNA was extracted from the colonies obtained, and the amount expressed of Nanog was demonstrated by quantitative PCR. From the cells in which three genes were introduced and which were treated with a histone deacetylase inhibitor, alkaline phosphatase-positive cell group (colonies) was formed, and it was confirmed that the expression of Nanog in these colonies was significantly higher than the alkaline phosphatase-negative colonies.
  • HDAC histone deacetylase
  • W1, W2, W3, W4, W5 and W6 represent the number of each well of the 6-well plate used in Example 12.
  • FIG. 4 Figure shows the characterization of human iPS clone 1-8.
  • a-e Morphology of its parental fibroblast (lot. 5F0438) (a), human iPS clone 1-8 cells cultured on MEF feeder cells (b), human iPS clone 1-8 cells in mTeSR1 medium (c), clone 2-4 cells (d), and clone 3-2 cells (e) in mTeSR1 medium.
  • f-g Growth curve of clone 1-8. Arrows indicate the dates of examinations. Square indicates the period for counting cell numbers to estimate cell proliferation rate.
  • h Multicolor karyogram image indicates normal karyotype of iPS clone 1-8 derived cell at day 101.
  • FIG. 5 Figure shows characterization of transcription factor, cell surface antigens and alkaline phosphatase activity in human iPS clone 1-8 cell.
  • a-h Immunohistochemical staining of human iPS cells (clone 1-8) with Nanog (a), SSEA-3 (b), SSEA-4 (c), TRA-1-60 (d), TRA-1-81 (e), CD9 (f), CD24 (g), Thy-1 (also called CD90) (h). Green fluorescent staining indicates that human iPS clone 1-8 expresses all of these surface antigens.
  • Alkaline phosphatase staining indicates that iPS clone 1-8 is alkaline phosphatase positive.
  • FIG. 6 Figure shows gene expression analysis of human iPS clone 1-8 cells.
  • a RT-PCR analysis of hES marker gene expression in clone 1-8 and its parental fibroblast (NeoFB). Genes were detected at 30 cycles except for CYP26A1 (35 cycles).
  • b Silencing of four transgenes in clone 1-8. Crude fibroblasts obtained on 17 days after gene transduction were used as control. “exo” primer sets selectively detected exogenous expression and “total” primer sets included endogenous expression.
  • FIG. 7 Figure shows global gene expression analysis of human iPS clonel-8 cells. Scatter plots show comparison of global gene expression between human iPS clone-1-8 cells cultured in mTeSR and H14 hES cells with MEFs (GSM151741 from public database GEO)(a), or between clone 1-8 and its parental fibroblasts (b). Symbols of ES cell specific genes were pointed with lines in both scatter plots. Expression intensity was shown in colorimetric order from red (high) to green (low).
  • FIG. 8 Figure shows global gene expression analysis by gene trees.
  • Cells were clustered in the gene tree based on a set of genes by the International Stem Cell Initiative (except PTF1A because of no array in the chip).
  • Samples were designated 1-8 mTeSR for clone-1-8 cultured in mTeSR, 1-8CM for clone 1-8 cultured in MEF-conditioned medium, 5F0438 for the parental fibroblasts, hES1, hES2, hES3 (GSM194307, GSM194308, GSM194309) for Sheff 4 line cultured on MEF, hES4, hES5 (GSM194313, GSM194314) for Sheff 4 line cultured on matrigel, hES6, hES7 (GSM151739, GSM151741) for H14 line cultured on MEF, Fibroblasts1 for GSM96262, Fibroblasts2 for GSM96263, and Fibroblasts3 for GSM96264, respectively
  • FIG. 9 Figure shows global gene expression analysis by gene trees. Cells were clustered in the gene tree based on a set of genes correlated with Nanog gene expression in human ES cells (seven GEO data) between the ratio of 0.99 and 1 when compared with fibroblasts (three GEO data).
  • Samples were designated 1-8 mTeSR for clone-1-8 cultured in mTeSR, 1-8CM for clone 1-8 cultured in MEF-conditioned medium, 5F0438 for the parental fibroblasts, hES1, hES2, hES3 (GSM194307, GSM194308, GSM194309) for Sheff 4 line cultured on MEF, hES4, hES5 (GSM194313, GSM194314) for Sheff 4 line cultured on matrigel, hES6, hES7 (GSM151739, GSM151741) for H14 line cultured on MEF, Fibroblasts1 for GSM96262, Fibroblasts2 for GSM96263, and Fibroblasts3 for GSM96264, respectively. Expression intensity was shown in colorimetric order from red (high) to green (low).
  • FIG. 10 The parts of the Oct3/4 promoter including the distal enhancer (Oct3/4-Z1) and the proximal promoter region (Oct3/4-Z2) and the parts of the Nanog promoter including the proximal promoter region (Nanog-Z1, -Z2) were analyzed for the methylation of CpG (a). Ratio of methylation on CpG shown by circle is indicated by the percentage (b).
  • FIG. 11 Figure shows teratoma that was derived from human iPS-1-8 mTeSR cells cultured for 94 days.
  • Human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 56 days after injection.
  • a HE and alcian blue staining of formaldehyde fixed teratoma tissues.
  • the teratomas contained tissues representative of the three germ layers.
  • ne neural epitherium
  • ca cartilage
  • et endodermal tract.
  • b-d tissues originated from transplant were distinguished from host tissues by HuNu staining.
  • FIG. 12 Figure shows teratoma formation.
  • Teratoma 1 (T-1) was derived from human iPS-1-8 mTeSR cells cultured for 94 days. The human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 56 days after injection.
  • Teratoma 2 (T-2) was derived from human iPS-1-8 mTeSR cells cultured for 102 days. The human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 48 days after injection.
  • smooth muscle cells positive for ⁇ -SMA
  • secretary epithelium positive for MUC-1 were observed in addition to three germ layers observed in FIG. 11 .
  • FIG. 13 Figure shows teratoma formation.
  • Teratoma 3 (T3) was derived from human iPS-1-8 mTeSR cells cultured for 114 days. Human iPS-1-8 mTeSR cells were injected into SCID mouse testis and analyzed 42 days after injection. Three germ layers similar to FIGS. 11 and 12 were observed.
  • T-F1 and F2 figure shows teratoma that were derived from freeze-thawed iPS-1-8 mTeSR cells cultured for 134 days (passage 19).
  • Human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 46 days (T-F1) and 48 days (T-F2) after injection. Tissues consisting of three germ layers were observed. Melanocytes were also observed in T-F2 experiment. Pluripotency were maintained even via freezing and thawing.
  • FIG. 14 Figure shows the existence of four transgenes in human iPS clone 1-8.
  • Oct3/4, Sox2, and Klf4 transgenes were detected by Southern blot analysis.
  • Human iPS clone-1-8 was estimated to have approximately ten copies of both Oct3/4 transgenes and Sox2 transgenes, and a single copy of Klf4 transgene.
  • Genomic PCR proved c-Myc transduction.
  • Primer set was designed to include whole second intron. Black arrows indicate the position of transgene.
  • White arrow indicates the position of endogenous c-Myc.
  • FIG. 15 Figure shows hES maker gene expression profile in ALP positive colonies induced by four genes (Oct4, Sox2, Klf4 and c-Myc). Colonies were stained for alkaline phosphatase at 17 days post 4 genes transduction. All ALP(+) colonies were dissected and determined their hES marker gene expressions. a, the number of colonies expressing Nanog, TDGF1, Dnmt3b, Zfp42, FoxD3, TERT, CYP26A1, and GDF3. b, morphologies of octa-positive colonies. c-d, the number of hES cell marker genes categorized by individual experiments.
  • FIG. 16-FIG . 22 Figure shows morphologies of four gene (Oct4, Sox2, Klf4 and c-Myc) induced colonies categorized by gene expression profile of ES cell related 8 genes (Nanog, TDGF1, Dnmt3b, Zfp42, FoxD3, TERT, CYP26A1, and GDF3) as well as alkaline phosphatase activity. Circles indicate the picked-up colony.
  • Undifferentiated stem cells present in a human postnatal tissues are undifferentiated stem cells which are present in human postnatal skin, bone marrow, adipose tissue, skeletal muscle tissue, and peripheral blood, and tissues concomitant to birth such as placenta, umbilical cord and cord blood and in which the Tert, Nanog, Oct3/4 and Sox2 genes have not undergone epigenetic inactivation, and, by using a combination of induced expression of the three genes of Oct3/4, Sox2 and Klf4 and the induced expression of c-Myc or the addition of a histone deacetylase inhibitor, can induce human pluripotent stem cells having a long-term self-renewal ability and the pluripotency of differentiating into ectoderm, mesoderm and endoderm.
  • the above human pluripotent stem cells may further have a potential of differentiating into primordial germ cells.
  • Undifferentiated stem cells present in a human postnatal tissue can be cultured using a plastic culture dish.
  • a 2% serum is used, PDGF and EGF or FGF-2 may be added to the culture medium, to which IGF or insulin may further be added.
  • a culture medium containing serum is used for a long term culture, properties of undifferentiated stem cells present in a human postnatal tissue may change, and thus it is important to limit the serum concentration to 2% or less and the number of passages to about twice.
  • the MAPC medium or the FBM medium for example, is used as the culture medium.
  • an incubator at 37° C. and 5% CO 2 is used similarly to common culture cells. It is also possible to use low concentration oxygen, for example a 3% oxygen concentration.
  • Culture plates are preferably coated with fibronectin etc.
  • the human pluripotent stem cells of the present invention induced from undifferentiated stem cells present in a human postnatal tissue may be cultured using a plastic culture dish.
  • cells after the four genes of Oct3/4, Sox2, Klf4 and c-Myc were introduced therein are cultured in a MEF-conditioned human ES cell medium to which 10 ng/ml bFGF and 10 ng/ml activin A had been added, and the medium is changed every 1 to 2 days.
  • the pluripotent stem cells induced are detached with dispase, collagenase, trypsin or the like, and subcultured.
  • the induced human pluripotent stem cells are plated on a MEF-covered plastic culture dish, and cultured in a human ES cell medium supplemented with 10 ng/ml bFGF.
  • the supporting cells are not used, the induced human pluripotent stem cells are plated on a matrigel-coated plastic culture dish, and cultured in a MEF-conditioned human ES cell medium supplemented with 10 ng/ml bFGF and 10 ng/ml activin A. In either of the culture methods, the medium is changed every 1 to 2 days.
  • an adenovirus vector is constructed carrying cDNA having the sequence of coding region of the mouse-derived cationic amino acid transporter (mCAT) gene (see Example 2, Table 1), which is then introduced into the packaging cell based on the HEK293 cell to prepare a virus solution of the adenovirus vector.
  • mCAT mouse-derived cationic amino acid transporter
  • the virus solution is added at a multiplicity of infection (m.o.i.: the ratio of the number of virus particles to the number of cells) of 1 to 20 to undifferentiated stem cells present in a human postnatal tissue in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation, and thus undifferentiated stem cells expressing mCAT are prepared.
  • m.o.i. the ratio of the number of virus particles to the number of cells
  • a retrovirus vector carrying cDNA encoding human Oct3/4, a retrovirus vector carrying cDNA encoding human Sox2, a retrovirus vector carrying cDNA encoding human Klf4, and a retrovirus vector carrying cDNA encoding human c-Myc are constructed (Table 1), and then each of them is introduced into the packaging cell capable of producing an ecotropic recombinant virus constructed based on the HEK293 cell to prepare a virus solution of retrovirus vectors.
  • the human pluripotent stem cells of the present invention after being suspended in the Cryopreservation Medium For Primate ES Cells (manufactured by ReproCELL), preferably are rapidly frozen in liquid nitrogen, and stored in a liquid nitrogen storage vessel.
  • the pluripotent stem cells of the present invention that were stored frozen are rapidly thawed by suspending in a medium that had been warmed to 37° C., removing the medium from the suspension by centrifugation, and then suspending again in a fresh medium to start culturing.
  • siRNA and a compound that inhibit the induction from undifferentiated stem cells present in a human postnatal tissue in which the Tert, Nanog, Oct3/4 and Sox2 genes have not undergone epigenetic inactivation to human pluripotent stem cells are searched using a high throughput screening system.
  • siRNA represents a double stranded RNA that comprises about 19 base pairs which is part of the sequence of a gene, and that has an effect of inhibiting the translation of the gene to the protein due to RNA interference.
  • siRNA of a gene is introduced into a cell, only the function carried by the protein can be specifically deleted.
  • siRNA library in a specific cell, the state in which the function of only one gene among all the genes was deleted can be observed individually for every gene.
  • siRNA library it is possible to identify a gene that inhibits the induction from a undifferentiated stem cell present in a human postnatal tissue in which the Tert, Nanog, Oct3/4 and Sox2 genes have not undergone epigenetic inactivation to a human pluripotent stem cell.
  • an inhibitor of the gene using this method it is possible to induce human pluripotent stem cells from undifferentiated stem cells present in a human postnatal tissue.
  • siRNA library those in which four siRNA's are synthesized for each gene of a total of about 25,000 human genes, mixed in equal amounts, and dispensed in a 384-well culture plate are used, and subjected to screening (manufactured by Qiagen). Details of it are as follows. Four siRNA's synthesized for each gene are mixed in equal amounts, and 2.5 pmol each is dispensed in each well of a 384-well culture plate. In order to cover all of about 25,000 genes, seventy three 384-well culture plates are needed. To predetermined wells of each plate, 2.5 pmol each of the positive and negative control siRNAs is dispensed in order to determine the introduction efficiency of siRNA into the cell and to correct for efficiency of each plate. The final concentration of siRNA is 50 nM.
  • siRNA was prepared, a primary screening is conducted.
  • methods of detecting the activation of genes that could be an index for differentiation into the pluripotent stem cells of the present invention such as Tert, Nanog, Oct3/4 and Sox2 in the cell to be targeted there are the promoter reporter assay of the gene of interest [as the reporter gene, EGFP (enhanced green fluorescence protein), luciferase etc.], the immunocytochemical staining method to said gene product, and the like.
  • the lipofection method may be used for transfection of siRNA to the cell.
  • 0.1 ⁇ l of LipofectAMINE RNAiMax manufactured by Invitrogen
  • Opti-MEM manufactured by Invitrogen
  • target cells prepared at 20 to 25 cells/ ⁇ l in up to 40 ⁇ l of the medium are dispended to every well on the 73 plates to introduce siRNA into the cell.
  • the number of cells and the amount of the medium are determined as appropriate depending on the cell used for screening.
  • cells in which a reporter system has been permanently integrated with a retrovirus vector (including lentivirus) or cells 1 to 7 days after infection with an adenovirus vector carrying the reporter system of interest are used for cells such as adult stem cells for which gene introduction by the lipofection method or the calcium phosphate method is difficult.
  • the reporter system of the present invention is applied to cultured lined cells such as HEK293 cells and Hela cells, the reporter system should be introduced one day in advance or simultaneously with siRNA by a gene introduction method suitable for respective cells.
  • the entire 73 plates to which transfection reagents and cells have been dispensed are cultured in a culturing equipment maintained at 37° C. and 5% CO 2 for 2 to 7 days.
  • the culturing time may vary as appropriate depending on the type of the cell, the gene to be detected, and the like.
  • alkaline phosphatase staining As a method of selecting siRNA that promotes the induction from undifferentiated stem cells present in a human postnatal tissue to human pluripotent stem cells, alkaline phosphatase staining can be used. As the alkaline phosphatase staining method, the following method can be mentioned.
  • cells are fixed in a 10% formaldehyde solution at room temperature for 2 to 5 minutes, washed with a phosphate buffer etc., and a chromogenic substrate of alkaline phosphatase, nitroblue tetrazolium chloride/5-bromo-4-chloro-3′-indolyl phosphatase para-toluidine salt solution (hereinafter referred to as the NBT/BCIP solution) is added and reacted at room temperature for 20 to 30 minutes.
  • NBT/BCIP solution a chromogenic substrate of alkaline phosphatase, nitroblue tetrazolium chloride/5-bromo-4-chloro-3′-indolyl phosphatase para-toluidine salt solution
  • the method used is conducted similarly to the above screening used for siRNA.
  • the compound in stead of siRNA is spotted in each well, the cell is dispensed and cultured, and similarly determined. The transfection procedure is not necessary.
  • the retrovirus vector plasmids for the four genes of Oct3/4-pMx, Sox2-pMx, Klf4-pMx and c-Myc-pMx constructed as in Table 1 were introduced into the packaging cell, the Plat-E cell [Experimental Hematology, 2003, 31 (11): 1007-14], using Fugene HD (manufactured by Roche). During 24 to 48 hours after retrovirus vector introduction, the medium was replaced with a medium suitable for the cell to which gene is to be introduced. After culturing the Plat-E cell to which retrovirus vector was introduced for more than 4 hours, the supernatant was recovered and passed through a filter of 45 ⁇ m in diameter (manufactured by Millipore). By the above procedure, the retrovirus vector solutions of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) were prepared.
  • the retrovirus vector plasmids for the three genes of Oct3/4-pMx, Sox2-pMx, Klf4-pMx and c-Myc-pMx were introduced into the packaging cell, the Plat-E cell, using Fugene HD (manufactured by Roche). During 24 to 48 hours after retrovirus vector introduction, the medium was replaced with a medium suitable for the cell to which gene is to be introduced. After culturing the Plat-E cell to which retrovirus vector was introduced for more than 4 hours, the supernatant was recovered and passed through a filter of 45 ⁇ m in diameter (manufactured by Millipore). By the above procedure, the retrovirus vector solution of the three genes (Oct3/4, Sox2 and Klf4) were prepared.
  • an oncogene c-Myc
  • c-Myc an oncogene
  • an amphotropic retrovirus vector which can infect into human cells
  • mCAT1 mouse-derived cationic amino acid transporter 1
  • an adenovirus vector carrying cDNA having the sequence of coding region of the mouse-derived cationic amino acid transporter (mCAT1) gene was constructed. Specifically, Adeno-X Expression System 1 kit (manufactured by TakaraBio Clontech) was used. In Adeno-X Expression System 1 kit, based on the experimental method attached to the kit by TakaraBio, the mCAT1 gene was subcloned into the multi-cloning site of a vector called pShuttle.
  • an expression cassette was excised by the PI-Sce I site and the I-Ceu I site, cleavage sites on both ends of the expression cassette of pShuttle, and a DNA fragment containing the desired gene was inserted in between the PI-Sce I site and the I-Ceu I site in the Adeno-X Viral DNA in the above kit, which was then treated with a restriction enzyme Swa I to remove adenovirus DNA for which integration was unsuccessful.
  • the plasmid was transformed into an E. coli DH5 strain, whether the desired gene was correctly introduced into adenovirus DNA or not was confirmed by restriction enzyme treatment, PCR etc.
  • the plasmid was prepared in large quantities, and cleaved with the Pac I restriction enzyme.
  • the gene was introduced into the HEK293 cells (MicroBix) plated in six wells using Lipofectamin 2000 (manufactured by Invitrogen), and two weeks later when the cell exhibited a cytopathic effect (CPE), the cells were collected as they are in the medium.
  • CPE cytopathic effect
  • the virus suspension thus prepared was added to one 100 mm plastic culture dish equivalent of HEK293 cells (5 ⁇ 10 6 cells) to infect the cells, the virus was propagated. Furthermore, after virus was prepared in large quantities using four 150 mm plate equivalent of HEK293 cells, virus was purified using the Adenovirus Purification kit (manufactured by Clontech), and stored frozen at ⁇ 80° C.
  • the titer (plaque forming units, PFU) of the mCAT1 adenovirus vector was determined using the Adeno-X Rapid Titer kit.
  • HEK293 low cells were plated at a concentration of 5 ⁇ 10 4 cells/500 ⁇ l per well.
  • Fifty ⁇ l of serially diluted (from 10 ⁇ 2 to 10 ⁇ 7 ) virus vector was mixed with 500 ⁇ l of the medium, and then used to infect the cells. After culturing at 5% CO 2 and 37° C. for 48 hours, the medium was aspirated off, the cells were dried for 5 minutes, and then using 500 ⁇ l of cold 100% methanol the cells were fixed by allowing to stand at ⁇ 20° C. for 10 minutes.
  • DAB diaminobenzidine
  • phosphate buffer 250 ⁇ l of the DAB (diaminobenzidine) solution (10-fold DAB concentrate was diluted with a stable peroxidase buffer) was added to wells, and was allowed to stand at room temperature for 10 minutes. After aspirating off DAB, 500 ⁇ l of phosphate buffer was added. Using a 20 ⁇ objective lens, the number of brown positive cells in six viewing fields was counted.
  • alkaline phosphatase activity which is a characteristic of pluripotent stem cells was conducted in the following manner. After removing the culture medium, a 10% formalin neutral buffer solution was added to wells, and cells were fixed at room temperature for 5 minutes. After washing with a phosphate buffer etc., a chromogenic substrate of alkaline phosphatase, 1 step NBT/BCIP (manufactured by Pierce) was added and reacted at room temperature for 20 to 30 minutes. Cells having alkaline phosphatase activity were all stained blue violet.
  • target gene of each colony including an alkaline phosphatase-positive colonies was determined using quantitative PCR in the following manner. Colonies developed by the induction of pluripotent stem cells were harvested, and RNA was extracted using the Recoverall total nucleic acid isolation kit for FFPE (manufactured by Ambion). After synthesizing cDNA from the extracted RNA, the target gene was amplified using the Taqman Preamp mastermix (manufactured by Applied Biosystems).
  • the Taqman gene exprESsion assay (manufactured by Applied Biosystems) was used. The following shows the name of the target gene and the product code of each primer.
  • Human Hprt Hs99999909_m1, human Nanog: Hs02387400_g1, human Tert: Hs00162669_m1, Mouse Hprt: Mm01545399_m1, mouse Nanog: Ma02019550_s1.
  • cDNA extracted from mesenchymal stem cells established by the following manner was used.
  • the cell mass thus obtained was resuspended in 10 ml of MSCGM medium, and plated on a 100 mm plate at a concentration of 10 5 cells/cm 2 and cultured at 37° C. Seven days later, the medium was changed. At this time, the suspended cells in the old medium were collected by centrifuging at 300 g and 4° C. for five minutes, and were returned to the cells together with the fresh medium. On day 13 when the adherent cells became confluent, the supernatant was removed, non-adherent cells were washed off with a phosphate buffer, and adherent cells were collected by detaching with a 0.05% trypsin-EDTA solution and plated at a concentration of 3000 cells/cm 2 . RNA was collected from the cells of the third subculture, and cDNA was synthesized.
  • human adult bone marrow-derived cells (trade name: Human Bone Marrow-Derived Mononuclear Cell) containing undifferentiated stem cells present in a postnatal human adult bone marrow tissue, the cells were established under the low serum (2%) and the high serum (10%) culture conditions, and were used in the experiment for inducing pluripotent stem cells.
  • hBMMNCs frozen human bone marrow-derived mononuclear cells
  • Lot 060809B female, 20 years old, white/and hBMMNCs (manufactured by Lonza)
  • Lot 060470B female, 20 years old, black
  • the cell mass thus obtained was resuspended, and plated at a concentration of 10 5 cells/cm 2 on a 100 mm plate coated with 10 ng/ml fibronectin.
  • Growth factors 10 ng/ml PDGF-BB (manufactured by Peprotech), 10 ng/ml EGF (manufactured by Peprotech), 10 ng/ml IGF-1 (manufactured by Peprotech)] were added. Three days later, growth factors were only added. Seven days later, the suspended cells and the medium were collected except the adherent cells, and centrifuged at 300 g and 4° C. for five minutes. After the supernatant was removed, the cells were resuspended in a fresh medium.
  • the cell suspension was returned to the original 10 cm dish, and growth factors were added thereto.
  • the adherent cells became confluent, the supernatant was removed, non-adherent cells were washed off with a phosphate buffer, and adherent cells were collected by detaching with a 0.05% trypsin-EDTA solution, and using a cell banker (manufactured by Juji Field), the primary culture was stored frozen.
  • the cells were established using a MSCGM medium (manufactured by Lonza) containing 10% FBS under the high serum condition.
  • the Human Bone Marrow-Derived Mononuclear Cells were plated at a concentration of 10 5 cells/cm 2 in a 100 mm plate to which 10 ml of the MSCGM medium had been added, and cultured at 37° C. Seven days later, the suspended cells and the medium were collected except the adherent cells, and centrifuged at 300 g and 4° C. for five minutes, and after the supernatant was removed, the cells were resuspended in a fresh medium.
  • the cell suspension was returned to the original 10 cm dish, and culturing was continued. On day 13 when the adherent cells became confluent, the supernatant was removed, non-adherent cells were washed off with a phosphate buffer. Adherent cells were collected by detaching with a 0.05% trypsin-EDTA solution, and using a cell banker (manufactured by Juji Field), the primary culture was stored frozen.
  • the wells were washed with the Hank's balanced salt solution, and then colonies were surrounded by a cloning ring (manufactured by Iwaki) to the bottom of which silicone grease had been applied.
  • a cloning ring manufactured by Iwaki
  • One hundred ⁇ l of the Detachment Medium For Primate ES Cells (manufactured by ReproCELL) was added in the ring and cultured at 37° C. for 10 to 20 minutes.
  • the cell suspension in the ring containing the detached colony was added to 2 ml of the MEF-conditioned ES medium, and plated in one well of a MEF-coated 24-well plate. After culturing at 37° C. for 8 to 14 hours, the medium was changed, and subsequently medium change was continued every two days, and 8 days later a second subculture was carried out.
  • the medium was removed, washed with the Hank's balanced salt solution, the Detachment Medium For Primate ES Cells (manufactured by ReproCELL) was added, cultured at 37° C. for 10 minutes, and 2 ml of the medium was added to stop the reaction.
  • the cell suspension was transferred to a centrifuge tube, and centrifuged at 4° C. and 200 g for 5 minutes to remove the supernatant.
  • the cells were resuspended in the MEF-conditioned ES medium, and plated in 4 wells of the MEF-coated 24-well plate. Medium change was continued every 2 days, and seven days after the second subculture, the cells were subjected to alkaline phosphatase staining, and the cloned colony-derived cells were stained blue violet.
  • Nanog and Tert were expressed by the colony of alkaline phosphatase activity-positive pluripotent stem cells.
  • the amount expressed of Nanog was as much as 30-fold higher.
  • the expression of Tert was noted only in said pluripotent stem cells, and not in the mesenchymal stem cells. In the cells that did not form colonies despite the introduction of the four genes, Nanog or Tert was not expressed ( FIG. 1 ).
  • the pluripotent stem cells were obtained from the low serum culture group but not at all from the high serum culture group (Lot 060809B and Lot 060470B) (Table 2). Also, culturing under the low serum condition was suitable for the maintenance of the undifferentiated cells.
  • Neonatal Normal Human Skin Fibroblasts primary culture
  • Neonatal Normal Human Skin Fibroblasts primary culture, manufactured by Lonza, Lot 5F0438
  • MCDB202 modified medium a medium containing 2% fetal bovine serum, 5 ⁇ g/ml insulin, 50 ⁇ g/ml gentamycin, 50 ng/ml amphotericin-B (FBM medium, manufactured by Lonza) to obtain 12 ml of a cell suspension.
  • Example 2 Fourteen hours later, the medium was removed, and the mCAT1 adenovirus vector prepared in Example 2 at an amount equivalent to a m.o.i. of 5 in 500 ⁇ l of the Hank's balanced salt solution per well was added, and was infected at room temperature for 30 minutes. To each well, 2 ml of the FBM medium was added respectively, and cultured at 37° C.
  • the medium of each well was replaced with 2 ml of the retrovirus vector solution (polybrene at a final concentration of 4 ⁇ g/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours.
  • the virus supernatant was removed and replaced with the MEF-conditioned ES medium. Then medium change with the MEF-conditioned ES medium was continued every two days, and fourteen days after the introduction of the four genes, one well of the 6-well plate was subjected to alkaline phosphatase staining. As a result, six pluripotent stem cell-like alkaline phosphatase-positive colonies were obtained. Alkaline phosphatase-positive colonies were composed of markedly smaller cells than the neonatal normal human skin fibroblasts.
  • Nanog and Tert were expressed by the colonies of alkaline phosphatase activity-positive pluripotent stem cells.
  • the neonatal normal human skin fibroblasts before the introduction of the four genes did not express Nanog, whereas in the case of the cells after the introduction of the four genes, 9-fold as much in the cells that are not forming colonies and 18-fold as much expression of Nanog in the alkaline phosphatase activity-positive colonies were observed ( FIG. 2 ).
  • the expression of Tert was only noted in the alkaline phosphatase activity-positive colonies.
  • the pluripotent stem cells are defined by the characteristics of alkaline phosphatase activity-positive and Nanog-positive and Tert-positive. Also, the neonatal normal human skin fibroblasts were confirmed to be the cells that have a relatively high efficiency of inducing the pluripotent stem cells and that can express Nanog by the introduction of the four genes.
  • Colonies of the pluripotent stem cells were isolated in the following manner. On day 17 after gene introduction, six colonies with a characteristic shape were selected from the remaining wells. After washing the wells with the Hank's balanced salt solution, colonies were surrounded by a cloning ring (manufactured by Iwaki) to the bottom of which silicone grease had been applied. One hundred ⁇ l of the Detachment Medium For Primate ES Cells (manufactured by ReproCELL) was added in the ring and cultured at 37° C. for 20 minutes. The cell suspension in the ring containing the detached colonies was added to 2 ml of the MEF-conditioned ES medium, and plated in one well of a MEF-coated 24-well plate.
  • the medium was changed, and subsequently medium change was continued every two days, and 8 days later a second subculture was carried out.
  • the medium was removed, the cells were washed with the Hank's balanced salt solution, the Detachment Medium For Primate ES Cells was added and cultured at 37° C. for 10 minutes, and 2 ml of the medium was added to stop the reaction.
  • the cell suspension was transferred to a centrifuge tube, and centrifuged at 4° C. and 200 g for 5 minutes, and the supernatant was removed.
  • the cells were resuspended in the MEF-conditioned ES medium, and plated on four wells of a MEF-coated 24-well plate. Seven days after the second subculture, in a subculturing method described below, the cells were plated on a 60 mm plastic culture dish of which bottom had been coated with matrigel at a concentration of 20 ⁇ g/cm 2 .
  • the induced pluripotent stem cells were subcultured every 5 to 7 days for maintenance and growth. From the plastic culture dish on which subculturing is to be conducted, the medium was removed, the cells were washed with the Hank's balanced salt solution, dispase or the Detachment Medium For Primate ES Cells was added, and cultured at 37° C. for 5 to 10 minutes. When more than half of the colonies were detached, the ES medium was added to stop the reaction, and the cell suspension was transferred to a centrifuge tube. When colonies precipitated on the bottom of the tube, the supernatant was removed, and the ES medium was added again for suspension. After examining the size of the colonies, any extremely large ones were divided into appropriate sizes by slowly pipetting. Appropriately sized colonies were plated on a matrigel-coated plastic culture dish with a base area of about 3 to 6 times that before subculture. The colony-derived pluripotent stem cells are being grown and maintained now.
  • the Neonatal Normal Human Skin Fibroblasts in the lot (Lot 5F0474) other than the above lot 5F0438 exhibited a favorable induction of pluripotent stem cells.
  • cells derived from young individuals or cells of which culturing time is short were thought to be suitable for the induction of the pluripotent stem cells.
  • human adult tissue-derived cells (trade name: Adult Normal Human Skin Fibroblasts, primary culture) containing undifferentiated stem cells present in a human adult skin, the induction of pluripotent stem cells of the present invention was carried out.
  • Example 2 Fourteen hours later, the medium was removed, and the mCAT1 adenovirus vector prepared in Example 2 at an amount equivalent to a m.o.i. of 5 in 500 ⁇ l of the Hank's balanced salt solution per well was added, and was infected at room temperature for 30 minutes. To each well, 2 ml of the FBM medium was added, and cultured at 37° C.
  • the medium of each well was replaced with 2 ml of the retrovirus vector solution (polybrene at a final concentration of 4 ⁇ g/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours.
  • the virus supernatant was removed and replaced with the MEF-conditioned ES medium.
  • medium change with the MEF-conditioned ES medium was continued every two days, and thirteen days after the introduction of the four genes, alkaline phosphatase staining was carried out.
  • Example 6 From comparison to Example 6, the neonate-derived cells among the skin fibroblasts had a higher efficiency of inducing the pluripotent stem cells. Also, among the Adult Normal Human Skin Fibroblasts, cells derived from younger donors had a higher transformation efficiency. From the foregoing, it was demonstrated that the efficiency of inducing the pluripotent stem cells decreases in an age-dependent manner.
  • Neonatal Normal Human Skin Fibroblasts primary culture, manufactured by Lonza, Lot 5F0439
  • a second subculture After culturing for six days until a 70 to 90% confluence could be obtained, the cells were detached using a 0.025% trypsin-EDTA solution (manufactured by Lonza), centrifuged at 4° C. and 200 g for 5 minutes, and the supernatant was removed.
  • the second subcultured cells collected were stored frozen using the cell banker.
  • the frozen second subculture cells were thawed in a 37° C. incubator, suspended in 12 ml of the FBM medium, centrifuged at 4° C. and 200 g for 5 minutes, and the supernatant was removed.
  • the cells were suspended, and plated at a concentration of 10 4 cell/cm 2 on a 100 mm plastic culture dish of which bottom had been coated with matrigel at a concentration of 20 ⁇ g/cm 2 (a third subculture).
  • the medium was removed, and the mCAT1 adenovirus vector prepared in Example 2 at an amount equivalent to a m.o.i. of 5 in 2 ml of the Hank's balanced salt solution was added, and was infected at room temperature for 30 minutes.
  • 10 ml of the FBM medium was added, and cultured at 37° C.
  • the medium Forty eight hours after the introduction of the mCAT-1 adenovirus vector, the medium was removed, and replaced with 10 ml of the retrovirus vector solution (polybrene at a final concentration of 4 ⁇ g/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours.
  • the virus supernatant was removed and replaced with the MEF-conditioned ES medium.
  • medium change with the MEF-conditioned ES medium was continued every two days, and fourteen days after the introduction of the four genes, alkaline phosphatase staining was carried out. As a result, five pluripotent stem cell-like alkaline phosphatase-positive colonies were obtained. By calculating based on the area of the bottom, this indicates that 0.83 colony per well of the 6-well plate was obtained (Table 2).
  • the induction of the human pluripotent stem cells of the present invention from undifferentiated stem cells present in the umbilical cord was attempted.
  • EBM-2 Endothelial Cell Medium kit-2 manufactured by Lonza (2% serum)
  • each of the EBM-2 medium 2.5 ml each of the EBM-2 medium was added to each well, and cultured at 37° C. Forty eight hours after the introduction of the mCAT-1 adenovirus vector, the medium of each well was replaced with 2 ml each of the retrovirus vector solutions (polybrene at a final concentration of 5 ⁇ g/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours. The virus supernatant was removed and replaced with the MEF-conditioned ES medium. Then medium change with the MEF-conditioned ES medium was continued every two days. Twelve days after the introduction of the four genes, colonies were confirmed.
  • the induction of the human pluripotent stem cells of the present invention from undifferentiated stem cells present in the umbilical cord was attempted.
  • the medium was removed, and the mCAT1 adenovirus vector at an amount equivalent to a m.o.i. of 1.25 to 5 in 500 ⁇ l of the Hank's balanced salt solution per well was added, and infected at room temperature for 30 minutes. 2.5 ml each of the SmGM-2 medium was added to each well, and cultured at 37° C.
  • the medium of each well was replaced with 2 ml each of the retrovirus vector solutions (polybrene at a final concentration of 5 ⁇ g/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours.
  • the virus supernatant was removed and replaced with the MEF-conditioned ES medium.
  • medium change with the MEF-conditioned ES medium was continued every two days. Thirteen days after the introduction of the four genes, colonies were confirmed. However, the induced colonies were not stained with alkaline phosphatase activity.
  • Femurs and tibias were extracted from 4 to 6 week-old mice (c57BL/6N lineage, 4-week-old, female) taking utmost care not to bring in any other tissue.
  • the collected bone was soaked in 70% ethanol for a short period of time, the cells that attached to the outside of the bone were killed to prevent the contamination of cells other than the bone marrow.
  • the bone was immediately transferred to IMDM (Iscove's Modified Dulbecco's Medium) (manufactured by SIGMA) to prevent the effect of the cells inside of the bone marrow.
  • IMDM Iscove's Modified Dulbecco's Medium
  • All of the treated bone was transferred to a mortar having IMDM, and was smashed with a pestle. After washing several times with IMDM, the bone was cut into pieces with scissors. After further washing with IMDM several times, bone fragments were transferred to centrifuge tubes.
  • the cells derived from mouse deep bone marrow were suspended in the MAPC medium, and plated at a concentration of 10 5 cells/cm 2 .
  • a dish previously coated with a phosphate buffer containing 10 ng/ml fibronectin (Becton Dickinson) was used.
  • growth factors 10 ng/ml PDGF-BB (manufactured by Peprotech), 10 ng/ml EGF (manufactured by Peprotech), 1000 units/ml LIF (manufactured by Chemicon)] were added at the time of use. Three days after plating, growth factors were only added without changing the medium.
  • non-adherent cells were washed off with the phosphate buffer, and adherent cells were collected by detaching with a 0.05% trypsin-EDTA solution (manufactured by Invitrogen), and using a cell banker (manufactured by Juji Field), the cells were stored frozen as the primary culture.
  • the primary culture cells that had been stored frozen were thawed in a 37° C. water bath, and suspended in 10 ml of the MAPC medium that is a medium containing 2% FBS. In order to remove DMSO in the frozen solution, it was centrifuged at 4° C. and 300 g for 7 minutes, and the supernatant was removed. The cell mass obtained was resuspended, and plated at a concentration of 2.5 ⁇ 10 3 cells/cm 2 on a 12-well plastic plate having the bottom which had been gelatin-coated with 0.1% gelatin/phosphate buffer, and 2 ml each of the MAPC medium was added (the second subculture).
  • the medium was removed, and 2 ml each of the four gene retrovirus vector solution prepared as in Example 1 was added thereto and cultured at 37° C. for 4 to 14 hours. Then the virus solution was removed, and replaced with the mouse ES medium [the ES medium to which a final concentration of 0.3% FBS (manufactured by Invitrogen), 1000 units/ml LIF (manufactured by Chemicon), and 0.1 mM 2-mercaptoethanol were added]. Then medium change with the mouse ES medium was continued every three days, and 5 to 7 days after the introduction of the four genes, said pluripotent stem cells formed colonies comprising mouse ES cell-like small cells. The colonies of the induced pluripotent stem cells were stained blue violet by alkaline phosphatase activity.
  • the mouse pluripotent stem cells of the seventh subculture were subcutaneously transplanted to the back of three syngeneic C57BL/6N mice at 3 ⁇ 10 5 cells/mouse, and 38 days later the teratoma that formed was extracted. Teratoma was formed in all three mice. From the extracted teratoma, slices were prepared, and differentiation potential into three germ layers was analyzed by immunological staining and histological staining (HE stain, alcian blue stain). As a result, MAP2-positive cells (the nervous system) and GFAP-positive cells (the nervous system) as the ectodermic system, skeletal muscle cells (myocytes) and cartilage tissues as the mesodermic system, and intestinal tract tissues as the endodermic system were observed.
  • HE stain, alcian blue stain histological staining
  • the mouse pluripotent stem cells were subcultured every 3 to 4 days.
  • the medium was removed from the plastic culture dish in which subculture is carried out, washed with phosphate buffer, a 0.05% trypsin-EDTA solution was added, and cultured at 37° C. for 5 minutes.
  • the ES medium was added to stop the reaction, and the cell suspension was transferred to a centrifuge tube. By centrifuging at 200 g for 5 minutes, the supernatant was removed, and after suspending the precipitate in the mouse ES medium, the cells were plated in a gelatin-coated plate at a concentration of 10 4 cells/cm 2 .
  • the pluripotent stem cells induced from the cells derived from the mouse bone marrow cultured in low serum in the same subculture method could be cultured for a long time.
  • pluripotent stem cells were induced from the postnatal mouse bone marrow-derived cells established under the low serum condition.
  • pluripotent stem cells Using cells derived from mouse bone marrow that is a mouse postnatal tissue, the induction of pluripotent stem cells was carried out with the introduction of three genes and histone deacetylase inhibitor treatment.
  • the primary culture cells derived from mouse bone marrow containing undifferentiated stem cells that had been stored frozen after preparing in a manner similar to Example 11 were plated at a concentration of 5 ⁇ 10 3 cells/cm 2 on a 24-well plastic plate (manufactured by Becton Dickinson) having the bottom which had been gelatin-coated with a 0.1% gelatin/phosphate buffer, and 2 ml each of the MAPC medium was added.
  • mice ES medium Three days later, the medium was replaced with the mouse ES medium [a final concentration of 0.3% FBS (manufactured by Invitrogen), 1000 units/ml LIF (manufactured by Chemicon) and 0.1 mM 2-mercaptoethanol were added to the ES medium at the time of use].
  • FBS manufactured by Invitrogen
  • LIF manufactured by Chemicon
  • 2-mercaptoethanol 0.1 mM 2-mercaptoethanol
  • mice ES medium change with the mouse ES medium was continued every 2 to 3 days. Twelve days after the introduction of three genes (human Oct3/4, Sox2 and Klf4) retrovirus vector, the cells were subcultured from each well of the 24-well plastic plate to each well of a 6-well plastic plate. A portion of it was also cultured in a 24-well plastic plate. Fifteen days after said three gene introduction and MS-275 treatment, the pluripotent stem cells formed colonies composed of mouse ES cell-like small cells. The colonies of said pluripotent stem cells were stained blue violet by alkaline phosphatase activity.
  • the amount expressed of the Nanog gene was confirmed by quantitative PCR, and the expression of mouse Nanog of colonies of pluripotent stem cells having alkaline phosphatase activity was confirmed ( FIG. 3 ).
  • the pluripotent stem cells were subcultured from each well of the 6-well plate to a gelatin-coated 100 mm plate. Subculture was continued similarly.
  • mice Twenty nine days after said three gene introduction and MS-275 treatment, the mouse pluripotent stem cells were subcutaneously transplanted to the back of syngeneic C57BL/6N mice at 2 ⁇ 10 7 cells/mouse, and 34 days later the teratoma that formed was extracted. From the extracted teratoma, slices were prepared, and differentiation potential into three germ layers was analyzed by immunological and histological staining (HE stain, alcian blue stain).
  • GFAP-positive cells the nervous system
  • keratin producing cells skin cells
  • smooth muscle actin-positive cells smooth muscle cells
  • bone tissues and cartilage tissues as the mesodermic system
  • intestinal tract tissues endodermal epithelium positive for MUC-1 as the endodermic system
  • mouse pluripotent stem cells was carried out with the introduction of three genes.
  • the primary culture cells derived from mouse bone marrow containing undifferentiated stem cells that had been stored frozen after preparing in Example 11 were plated at a concentration of 1 ⁇ 10 4 cells/cm 2 on a 24-well plastic plate (manufactured by Becton Dickinson) having the bottom which had been gelatin-coated with a 0.1% gelatin/phosphate buffer solution, and 2 ml each of the MAPC medium was added.
  • the pluripotent stem cells formed colonies composed of mouse ES cell-like small cells.
  • the medium was removed and then a 10% formalin neutral buffer solution was added to wells, and fixed at room temperature for 5 minutes. After washing with a phosphate buffer etc., the 1 step NBT/BCIP solution (manufactured by Pierce) comprising a chromogenic substrate of alkaline phosphatase was added and reacted at room temperature for 20 to 30 minutes. The colonies of said pluripotent stem cells were stained blue violet by alkaline phosphatase activity.
  • the amount expressed of the Nanog gene was confirmed by quantitative PCR, and the expression of mouse Nanog of colonies of pluripotent stem cells having alkaline phosphatase activity was confirmed.
  • pluripotent stem cells were carried out with the introduction of three genes.
  • the primary culture cells derived from mouse bone marrow containing undifferentiated stem cells that had been stored frozen after preparing in Example 11 were plated at a concentration of 1 ⁇ 10 4 cells/cm 2 on a 6-well plastic plate (manufactured by Becton Dickinson) the bottom of which had been gelatin-coated with a 0.1% gelatin/phosphate buffer solution, and the MAPC medium was added in 2 ml portions.
  • the medium was removed, the three gene (human Oct3/4, Sox2 and Klf4) retrovirus vector solution prepared as in Example 1 were added in 2 ml portions, and after culturing at 37° C. for 1 day, the virus solution was removed, and the MAPC medium was added in 2 ml portions.
  • the medium was replaced with the mouse ES medium [a final concentration of 0.3% FBS (manufactured by Invitrogen), 1000 units/ml LIF (manufactured by Chemicon) and 0.1 mM 2-mercaptoethanol were added to the ES medium at the time of use].
  • Medium change with the mouse ES medium was continued every 2 to 3 days.
  • the cells were subcultured from each well of the 6-well plastic plate to each well of a 10 cm plastic dish.
  • the pluripotent stem cells formed colonies composed of mouse ES cell-like small cells.
  • the medium was removed and then a 10% formalin neutral buffer solution was added to wells, and fixed at room temperature for 5 minutes. After washing with a phosphate buffer etc., the 1 step NBT/BCIP (manufactured by Pierce), a chromogenic substrate of alkaline phosphatase, was added and reacted at room temperature for 20 to 30 minutes. The colonies of said pluripotent stem cells were stained blue violet by alkaline phosphatase activity.
  • the amount expressed of the Nanog gene was confirmed by quantitative PCR, and the expression of mouse Nanog of colonies of pluripotent stem cells having alkaline phosphatase activity was confirmed.
  • the mouse pluripotent stem cells were subcutaneously transplanted on the back of syngeneic C57BL/6N mice at 2 ⁇ 10 7 cells/mouse, and 13 and 17 days later the teratoma that formed was extracted. Slices were prepared from the extracted teratoma, and differentiation potential into three germ layers was analyzed by immunological and histological staining (HE stain, alcian blue stain).
  • GFAP-positive cells the nervous system
  • smooth muscle actin-positive cells smooth muscle cells
  • bone tissues and cartilage tissues as the mesodermic system
  • intestinal tract tissues endodermal epithelium positive for MUC-1 as the endodermic system
  • the mouse pluripotent stem cells which were single-sorted based on GFP and SSEA-1 positive with FACSAria, were subcutaneously transplanted on the back of syngeneic C57BL/6N mice at 2 ⁇ 10 7 cells/mouse, and 13 and 14 days later the teratoma that formed was extracted. Slices were prepared from the extracted teratoma, and differentiation potential into three germ layers was analyzed by immunological and histological staining (HE stain, alcian blue stain).
  • neural tube derived cells positive for GFAP, Nestin or Neurofilament as ectodermic system and cartilage tissues as the mesodermic system, and intestinal tract tissues (endodermal epithelium positive for MUC-1 and alpha-fetoprotein) as the endodermic system were observed.
  • pluripotent stem cell were obtained by the forced expression of each of three genes of Oct3/4, Sox2, and Klf4 in undifferentiated stem cell present in a postnatal tissue.
  • the pluripotent stem cells showed an in vitro long-term self-renewal ability, and were expressed ES cell marker, Nanog expression and alkaline phosphatase activity, and the ability of differentiation of tissues derivative from all three germ layers (ectoderm, mesoderm and endoderm).
  • iPS Human induced pluripotent stem
  • human iPS-1-8 clone One of nine sub clones, termed human iPS-1-8 clone, was successfully expanded on MEF feeder cells in human ES medium supplemented with 0.1 mM 2-mercaptoethanol and 10 ng/ml bFGF or in mTeSR1 defined medium (Stem cell Technologies) on matrigel (Invitrogen)-coated culture dishes. Medium was changed for human iPS-1-8 clone culture everyday and usually treated with 5 to 20 ⁇ M of Y-27632 (Calbiochem) to avoid cell apoptosis triggered by the passaging procedures.
  • human induced pluripotent stem cells were washed with Hanks's balanced solution, incubated in 0.25% trypsin-EDTA (Gibco) at 37° C. for 3 minutes, and then added the culture medium to terminate the trypsin activity.
  • Human induced pluripotent stem cells were centrifuged at 300 ⁇ g at room temperature or 4° C. for 5 minutes and the supernatant was removed. Precipitated human induced pluripotent stem cells were re-suspended into culture medium. The pluripotent stem cells were usually split into new culture dishes using 1:4 to 1:6 splits. Human iPS-1-8 clone was frozen using Cell freezing solution for ES cells (Reprocell) according to the manufacture's manual.
  • Human iPS-1-8 clone was morphologically indistinguishable from typical human ES cell colonies that consist of small, round, and compact cells with defined edges when cultured on mitomycin-C treated mouse embryonic fibroblasts (MEFs) ( FIG. 4 ).
  • Human iPS-1-8 clone actively proliferated in mTeSR1 medium.
  • Human iPS-1-8 clone derived cells cultured in mTeSR1 medium was termed human iPS-1-8 mTeSR cells.
  • Human iPS-1-8 clone was able to be passaged more than 30 times, and cultured for more than half year after four factor infections ( FIGS. 4 f,g ).
  • Human iPS-1-8 mTeSR cells were able to be stored in liquid nitrogen and re-cultured in mTeSR medium in the presence of 5 to 20 ⁇ M of Y-27632. Population doubling time of human iPS-1-8 mTeSR cells was approximately 48.5 hours when analyzed between passages 19 to 26 which correspond to days 123 to 148 after four factor infection.
  • Karyotype analysis of long-term cultured human iPS-1-8 clone (1-8 mTeSR) was performed using giemsa stain and multicolor-FISH analysis.
  • Human iPS cells were pretreated with 0.02 ⁇ g/ml colecemid for 2 hours, followed by incubation with 0.075 M KCl for 20 minutes, and then fixed with Carnoy's fixative.
  • multicolor-FISH analysis cells were hybridized with the multicolor FISH probe (Cambio) and analyzed under DMRA2 fluorescent microscope (Leica).
  • Human iPS-1-8 mTeSR cells mainly maintained a normal karyotype (46XY) after long-term culture in mTeSR (68%) without any chromosomal translocation or deletion ( FIG. 4 h , Table 3).
  • alkaline phosphatase staining cells were fixed with 10% formalin neutral buffer solution (Wako) at room temperature for 5 minutes, washed with PBS, and incubated with alkaline phosphatase substrate 1 step NBT/BCIP (Pierce) at room temperature for 20-30 minutes. Cells having alkaline phosphatase activity were stained in blue violet.
  • NBT/BCIP Pieris-Bassham
  • cultured cells were fixed with 10% formaldehyde for 10 minutes and blocked with 0.1% gelatin/PBS at room temperature for 1 hour. The cells were incubated overnight at 4° C.
  • Nanog staining cells were permeabilized with 0.1% Triton X-100/PBS before blocking. The cells were washed with PBS for three times, and then incubated with AlexaFluor 488-conjugated secondary antibodies (Molecular Probes) and Hoechst 33258 at room temperature for 1 hour. After further washing, fluorescence was detected with an Axiovert 200M microscope (Carl Zeiss).
  • Human iPS-1-8 mTeSR cells were positive for alkaline phosphatase (hereinafter referred to as “ALP”) activity and the glycolipid antigens SSEA-3 and SSEA-4, the keratin sulfate antigens TRA-1-60 and TRA-1-81, and the protein antigens CD9, CD24, Thy-1 (CD90) staining ( FIG. 5 ).
  • ALP alkaline phosphatase
  • Biotin-labelled cRNA was reverse transcribed from 1 ⁇ g of total RNA according to Affymetrix technical protocols. Fifteen micrograms of cRNA was fragmented and hybridized to a Affymetrix U133 plus 2 GeneChip arrays at 45° C. for 16 hours and then washed and stained using the Affimetrix Fluidics (Affymetrix). The assays were scanned in the Affimetrix GCS3000 scanner, and the image obtained were analyzed using the GCOS software. Data from this experiment and GEO were investigated with the GeneSpring 7.3.1. software.
  • human induced pluripotent stem cell clone-1-8 cultured in mTeSR on matrigel (1-8 mTeSR) and its parental fibroblasts (5F0438) were analyzed based on a set of 21,080 genes with present flag call (P ⁇ 0.04) or marginal flag call (0.04 ⁇ P ⁇ 0.06) for both clone 1-8 and H14 hES line which is data from GEO (GSM151741), were used as a representative of human ES cells for comparison.
  • DNA microarray data for clone-1-8 cultured in mTeSR (1-8 mTeSR), clone 1-8 cultured in MEF-conditioned medium (1-8CM) and its parental fibroblasts (5F0438) were compared with DNA microarray data for Sheff 4 line cultured on MEF (hES1:GSM194307, hES2: GSM194308, hES3: GSM194309), Sheff 4 line cultured on matrigel (hES4: GSM194313, hES5: GSM194314), H14 line cultured on MEF (hES6: GSM151739, hES7: GSM151741), and three fibroblasts (GSM96262 for Fibroblasts1, GSM96263 for Fibroblasts2 and GSM96264 for Fibroblasts3).
  • the global gene expression profile of the human iPS cell line (clone 1-8) and its parental fibroblasts were analyzed.
  • Cluster analysis using the gene set defined by the International Stem Cell Initiative revealed that the human iPS cell line 1-8 clustered with human ES cell lines but separated from the parental fibroblasts ( FIG. 8 ).
  • the pearson correlation coefficient was 0.675 between human ES cell lines sheff4 and H14, the coefficient was 0.835 between human iPS cell line 1-8 and human ES cell line H14 ( FIG. 8 ).
  • This analysis indicate that human iPS cell line 1-8 had a similar gene expression pattern to the human ES cell lines H14.
  • the promoter regions of Nanog and Oct3/4 were analyzed for methylation of individual CpG sites.
  • Ten nanograms of bisulfite-treated genomic DNA was PCR-amplified with primers containing a T7-promoter and transcripts treated with RNase A.
  • fragments originating from a methylated CpG sequence contained a G instead of an A-base, they had a 16 Da higher molecular weight than those resulting from the corresponding non-methylated CpG.
  • This mass difference was detected using a MALDI-TOF mass spectrometer (Autoflex, Bruker Daltonics). The spectra produced by the mass spectrometer were analyzed using the EpiTYPER (Sequenom).
  • the percentage methylation of individual CpG sites was calculated using the area under the peak of the signal from the unmethylated and methylated fragments.
  • the percentage methylation of individual CpG sites were calculated using the area under the peak of the signal from the unmethylated and methylated fragments.
  • Table 9 lists up locations and sizes in genome corresponding to amplicon using for methylation analyses.
  • Table 10 lists up the primer sets using for methylation analyses.
  • the Oct3/4 proximal promoter including conserved region 1 (CR1), the Oct3/4 promoter distal enhancer including CR4 and the Nanog proximal promoter including Oct3/4 and Sox2 binding sites were examined ( FIG. 10 a ).
  • cytosine-phosphate-guanosine (CpG) dinucleotides in these regions are demethylated in clone 1-8 derived cells compared to the parental fibroblasts.
  • Human iPS-1-8 mTeSR cell-suspension (0.5 to 2 ⁇ 10 6 cells/mouse) was injected into the medulla of left testis of 7 to 8 week old SCID mice (CB17, Oriental Yeast) using a Hamilton syringe. After 6 to 8 weeks, the teratomas were excised under perfusion with PBS followed with 10% buffered formalin, and subjected to the histological analysis. Human iPS-1-8 mTeSR cells gave rise to teratomas 4 to 8 weeks after transplantation into testes of SCID mice.
  • HE hematoxylin-eosin
  • Type II collagen For Type II collagen, before the treatment with primary antibody a section was incubated with Hyaluronidase (25 mg/mL) for 30 minutes. Localization of antigens was visualized by using appropriate secondary antibodies (Alexa fluor 594 and 688, Molecular Probes, 1:600). Nuclei were stained with DAPI. Immunostained teratoma sections were analyzed under a fluorescence microscope (Axio Imager Z1, Zeiss).
  • FIG. 11 shows teratoma that was derived from human iPS-1-8 mTeSR cells cultured for 94 days (T1).
  • Human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 56 days after injection.
  • HE and alcian blue staining of teratoma tissues revealed that teratomas contained neural epitherium (positive for nestin) cartilage (positive for collagen II), endodermal tract (alpha-fetoprotein).
  • Human iPS-1-8 mTeSR cell derived tissues were distinguished from host tissues by HuNu staining.
  • FIG. 12 Human iPS-1-8 mTeSR cells which were cultured for 102 days and 114 days, were injected into SCID mouse testes and analyzed 48 days and 42 days (T3) after injection, respectively (T2, FIG. 12 , T3, FIG. 13 ). Tissues representative of three germ layers, neuroectoderm, mesoderm and endoderm, were observed. To confirm whether human iPS can be cryopreserved, human iPS-1-8 mTeSR cells were frozen down, stored in liquid nitrogen and recultured.
  • T-F1 and T-F2 Tissues representative of three germ layers, neuroectoderm, mesoderm and endoderm, were observed. Melanocytes were also observed in the T-F2 teratoma ( FIG. 13 ). Thus, pluripotency was maintained via freezing and thawing.
  • SNP genotyping was performed with the use of the GeneChip Human Mapping 500K Array Set (Affymetrix) according to the manufacture's protocol.
  • Human iPS-1-8 mTeSR cells cultured in mTeSR on matrigel, its parental fibroblasts (5F0438), and fibroblast (5F0416) derived from a different donor were analyzed for this assay.
  • the array set includes a StyI and a NspI chip. Two aliquots of 250 ng of DNA each were digested with NspI and StyI, respectively. Each enzyme preparation was hybridized to the corresponding SNP array (262,000 and 238,000 on the NspI and StyI array respectively).
  • HLA DNA typing was performed by utilizing hybridization of PCR-amplified DNA with sequence specific oligonucleotide probes (SSOP) (Luminex). Assays were performed to determine the HLA-A, HLA-B, HLA-Cw, HLA-DR, HLA-DQ, HLA-DP and Bw loci according to manufacturer's instructions.
  • Human iPS cells are promising materials in cell transplantation therapies, they would overcome immune rejection, because human iPS cells can be directly generated from patients' cells and must be the identical HLA type.
  • human pluripotent stem cell were obtained by the forced expression of each of four genes of Oct3/4, Sox2, Klf4, and c-Myc in undifferentiated stem cell present in a human postnatal tissue.
  • the human pluripotent stem cells showed an in vitro long-term self-renewal ability and the pluripotency of differentiation into ectoderm, mesoderm and endoderm.
  • the human pluripotent stem cells were expressed cell surface antigens SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, CD9, CD24, and CD90, and ES cell marker genes Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1.
  • the promoter regions of Nanog and Oct3/4 in the human pluripotent stem cells were demethylated compared to the parental fibroblasts.
  • the human pluripotent stem cells carries at least a single copy of Oct3/4, Sox2, Klf4, and c-Myc transgene.
  • the induced human pluripotent stem cells and the parental cells had almost the same SNP genotype each other, and HLA type of the induced human pluripotent stem cell was completely identical to that of the parental cell (undifferentiated stem cell present in a human postnatal tissue).
  • Two lots of neonatal fibroblasts (5F0416 and 5F0474) were seeded at 10 3 cells/cm 2 or 10 4 cells/cm 2 into 35 mm diameter wells of 6 well plates and cultured in FBM supplemented with FGM-2 SingleQuots (manufactured by Lonza) before the four genes transduction.
  • Cells were infected with mCAT1-adenovirus vectors at 2 ⁇ 10 5 ifu/well and then infected with the retroviral vectors carrying four genes as described in Example 6. Eight wells were prepared for this study (2 different lot and 2 different densities in duplicate).
  • Real-time quantitative PCR was performed with ABI PRISM 7900HT (manufactured by Applied Biosystems) using PCR primer sets (manufactured by Applied Biosystems, Nanog, Hs02387400_g1, Dnmt3b, Hs00171876_m1, FoxD3, Hs00255287_s1, Zfp42, Hs01938187_s1, TDGF1, Hs02339499_g1, TERT, Hs00162669_m1, GDF3, Hs00220998_m1, CYP26A1, Hs00175627_m1, GAPDH, Hs99999905_m1) to determine gene expression of human ES cell markers in colonies.
  • TDGF1, Dnmt3b Zfp42 FoxD3, GDF3, CYP26A1 and TERT genes Eight genes (Nanog, TDGF1, Dnmt3b Zfp42 FoxD3, GDF3, CYP26A1 and TERT genes) which were reported to express in human ES cells were selected as a pluripotent stem cell marker genes. A standard curves was generated for each primer pair. All expression values were normalized against GAPDH.
  • mice ES cells and mouse iPS cells form multilayered/aggregated colonies.
  • mouse ES cell like aggregated colonies which were induced by ectopic expression of four gene in human fibroblasts (e.g. colony #1-2-F and #1-2-B in FIG. 22 ). However, these colonies are all ALP ( ⁇ ).
  • Nanog gene expression was observed in 161 out of 163 ALP positive colonies and 16 out of 18 ALP negative colonies.
  • TERT and CYP26A1 genes were observed only in 26 and 24 colonies out of 163 ALP positive colonies respectively ( FIG. 15 a ).
  • Genes such as Nanog, TDGF, and Dnmt3b which are well know to be close association with the pluripotent state in human ES cells, and to be strongly downregulated upon their differentiation had higher tendency to be induced by the four gene transduction.
  • ALP positive colonies can be categorized into 40 groups based on the gene expression pattern of the eight human marker genes (Table 7). When colonies are categorized by the total number of eight marker genes expression, the distribution of colony number followed a normal distribution suggesting the presence of a stochastic process in the colony induction ( FIGS. 15 c,d ). In addition the efficiency of human ES cell marker gene expression in human fibroblasts was affected by the donor difference.
  • induced pluripotent stem cells can be isolated from small monolayer colonies comprising small cells with high nucleus to cytoplasm ratio not from fibroblastic colonies, defused colonies or multilayered colonies.
  • Table 8 summarizes all of experiments and results on the ALP positive colony number using human neonatal fibroblasts.
  • Adenovirus vector plasmids for mCAT1 were transfected into 29310 cells.
  • the mCAT1-adenoviruses were isolated from these cells by three freeze-thaw cycles, purified using Adenovirus purification kit (Clontech) and stored at ⁇ 80° C.
  • the titer of the vector stocks was determined by Adeno-X rapid titer kit (Clontech).
  • the replication deficient MMLV derived retrovirus vector pMx was used for the ectopic expression of human Oct3/4, Sox-2, c-Myc and Klf4.
  • Recombinant retroviruses were generated by transfecting vectors to the Plat-E packaging system (Morita et al., 2000) followed by incubation in FBM (Lonza) supplemented with FGM-2 SingleQuots (Lonza). Between 24 and 48 hours after the transfection, supernatant from the Plat-E culture was collected several times at intervals of at least 4 hours and passed through a 0.45 ⁇ m filter.
  • MEF-conditioned medium human ES medium (DMEM/F12 (Gibco) supplemented with 20% Knockout Serum Replacement (KSR, Invitrogen), 2 mM L-glutamine (Sigma), 1 ⁇ nonessential amino acids (Sigma), 10 ⁇ g/ml gentamycin), 10 ng/ml bFGF was conditioned on mitomycin-C treated MEF (Reprocell) for 20-24 hours, harvested, filtered through a 0.45 ⁇ m filter and supplemented with 0.1 mM 2-mercaptoethanol (Sigma) and 10 ng/ml bFGF before use.
  • DMEM/F12 Gibco
  • KSR Knockout Serum Replacement
  • 2 mM L-glutamine Sigma
  • 1 ⁇ nonessential amino acids Sigma
  • 10 ⁇ g/ml gentamycin 10 ng/ml bFGF was conditioned on mitomycin-C treated MEF (Reprocell) for 20-24 hours, harvested, filtered through a 0.45 ⁇
  • Neonatal Normal Human Skin Fibroblasts primary culture
  • Human neonatal dermal fibroblasts (Lonza; lot 5F0416) were cultured in FBM supplemented with FGM-2 SingleQuots. Three days before the 4 gene introduction, fibroblasts were seeded at 10 3 cells/cm 2 into 6 well plates. Eighteen hours later, the cells were mixed with the mCAT1 adenovirus vector solution in 500 ⁇ l Hanks' balanced salt solution, and incubated at room temperature for 30 min. The cells were then added to 2 ml of medium and cultured for 48 hrs.
  • the cells were incubated in 2 ml of the retrovirus/polybrene solution (mixture of equal volumes of the retrovirus vector suspension for each of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, supplemented with 5 ⁇ g/ml of polybrene) at 37° C. for 4 hrs to overnight.
  • the virus supernatant was replaced with the MEF-conditioned ES medium. Then medium was changed every days.
  • a colony with a characteristic shape was picked with forceps from a well.
  • the picked colony was transferred into a matigel-coated well in a 24-well plate and maintained in mTeSR defined medium supplemented with 10 ⁇ M Y-27632. Fourteen hours later the medium was changed. Medium change was continued every days.
  • a second culture was carried out.
  • human iPS-2-4 clone was sub-cloned and designated as human iPS-2-4 sub-clone.
  • Human iPS-2-4 sub-clone was successfully expanded in mTeSR1 defined medium (Stem cell Technologies) on matrigel (Invitrogen)-coated culture dishes.
  • mTeSR1 defined medium Stem cell Technologies
  • matrigel Invitrogen
  • mTeSR1 medium human iPS-2-4 mTeSR cells.
  • Medium was changed for human iPS-2-4 mTeSR cell culture everyday and usually treated with Y-27632 (Calbiochem) to avoid cell apoptosis after passaging.
  • Y-27632 Calbiochem
  • passaging cells were washed with Hanks's balanced solution, incubated in 0.25% trypsin-EDTA (Gibco) at 37° C. for 3 minutes, and then added the culture medium.
  • Human iPS-2-4 mTeSR cells were morphologically indistinguishable from typical human ES cells and human iPS-1-8 mTeSR cells consisting of small, round, and high nucleus to cytoplasm ratio cells with defined edges.
  • ALP alkaline phosphatase
  • human pluripotent stem cell were obtained by the forced expression of each of four genes of Oct3/4, Sox2, Klf4, and c-Myc in undifferentiated stem cell present in a human postnatal tissue.
  • the human pluripotent stem cells showed an in vitro long-term self-renewal ability, and were expressed ES cell marker genes Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1.
  • human neonatal dermal fibroblasts (Lonza; lot 5F0438) were cultured in FBM supplemented with FGM-2 SingleQuots. Three days before the 4 gene introduction, fibroblasts were seeded at 10 3 cells/cm 2 into 6 well plates. Eighteen hours later, the cells were mixed with the mCAT1 adenovirus vector solution in 500 ⁇ l Hanks' balanced salt solution, and incubated at room temperature for 30 min. The cells were then added to 2 ml of medium and cultured for 48 hrs.
  • the cells were incubated in 2 ml of the retrovirus/polybrene solution (mixture of equal volumes of the retrovirus vector suspension for each of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, supplemented with 5 ⁇ g/ml of polybrene) at 37° C. for 4 hrs to overnight.
  • the virus supernatant was replaced with the MEF-conditioned ES medium.
  • medium was changed every days.
  • a colony with a characteristic shape was directly picked with forceps from one of dishes. The picked colony was transferred into a matigel-coated well in a 24-well plate and maintained in mTeSR defined medium supplemented with 10 ⁇ M Y-27632.
  • Human iPS-3-2 clone actively proliferated in mTeSR1 medium.
  • mTeSR1 medium we termed these cells derived from human iPS-3-2 clone which culture in mTeSR1 medium as human iPS-3-2 mTeSR cells.
  • RNA from colonies were extracted using a RecoverAll Total Nucleic Acid Isolation kit (manufactured by Ambion). After the cDNA preparation, genes of interest were amplified using Taqman preamp (manufactured by Applied Biosystems).
  • human pluripotent stem cell were obtained by the forced expression of each of four genes of Oct3/4, Sox2, Klf4, and c-Myc in undifferentiated stem cell present in a human postnatal tissue.
  • the human pluripotent stem cells showed an in vitro long-term self-renewal ability, and were expressed ES cell marker genes Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1.
  • Table 1 shows the name of gene, the NCBI number, the virus vector in which said gene was inserted, insert size, the restriction site at the 5′-end, the restriction site at the 3′-end, the length of the translated region, the length of the 3′-untranslated region, clone ID, and the supplier of the four genes or the three genes and the receptor of mouse ecotropic retrovirus vector (mCAT: mouse-derived cationic amino acid transporter) used in Examples.
  • mCAT mouse-derived cationic amino acid transporter
  • Table 2 summarizes the number of alkaline phosphatase-positive colonies of Examples 4 to 7.
  • the number of subculture is attached.
  • the day of four gene introduction is a day when a retrovirus vector was infected.
  • Lot No. is that of Lonza products.
  • Age of donors is based on the donor information of Lonza products.
  • the number of colonies is the number of colonies composed of alkaline phosphatase-positive small cells per 10 cm 2 .
  • BM in Table 2 means “Bone Marrow”.
  • Table 3 summarizes the distribution of the karyotype of clone 1-8 at day 101. After the Giemsa stain, chromosome numbers were counted. 67 of 100 cells showed normal karyotype.
  • SNPs of clone 1-8 were consistent to that of parental cells in 464,069 (99.17%) of 467,946 of called SNPs and different from that of parental cells in 3,877 (0.83%) of them.
  • SNPs of clone 1-8 mTeSR were consistent to that of unrelated donor cells (5F0416) only in 284,950 (60.50%) of 470,960 of called SNPs and different from that of the unrelated cells in 186,010 (39.50%) of them.
  • neoFB Called SNP in both samples 470,960 ratio Consistent SNP 284,950 60.50% different SNP 186,010 39.50% No called SNP in neither 29,608 Table 6
  • the HLA-A, HLA-B, HLA-Cw and HLA-DR types of human iPS1-8 (1-8 mTeSR) and fibroblasts (5F0438 and 5F0416) were classified using hybridization of PCR-amplified DNA with sequence specific oligonucleotide probes (SSOP) (Luminex).
  • SSOP sequence specific oligonucleotide probes
  • Colonies were stained for alkaline phosphatase at 17 days post 4 genes transduction. All ALP (+) colonies and 18 ALP ( ⁇ ) colonies were dissected and determined their hES marker gene expression by RT-PCR. Each colony was categorized and counted the number. “+” represents gene expression, and “ ⁇ ” represents no detection by a 40 cycle RT-PCR using amplified cDNA samples.
  • the date of four gene introduction is a day when a retrovirus vector was infected.
  • the donor indicates lot number of Lonza products.
  • the number of colonies is the number of colonies composed of alkaline phosphatase-positive small cells per 10 cm 2 . ND: not determined.
  • Cells in a tissue that was lost in diseases etc. can be supplied by inducing human pluripotent cells from the undifferentiated stem cells harvested from a patient by using the induction method of the present invention, followed by inducing to differenciate into a necessary cell depending on diseases and then transplanting the cells to the patient.
  • the undifferentiated stem cells of the present invention present in a human postnatal tissue can be used to search drugs that promote the induction from said undifferentiated stem cells to human pluripotent stem cells by using markers such as Tert, Nanog, Sox2, Oct3/4 and alkaline phosphatase that direct the induction to human pluripotent stem cells. Said drugs can be used in stead of gene introduction and can enhance the induction efficiency of human pluripotent stem cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
US12/663,840 2007-06-15 2007-11-20 Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue Abandoned US20110039332A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007-159382 2007-06-15
JP2007159382A JP2008307007A (ja) 2007-06-15 2007-06-15 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
PCT/EP2007/010019 WO2009006930A1 (en) 2007-06-15 2007-11-20 Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/010019 A-371-Of-International WO2009006930A1 (en) 2007-06-15 2007-11-20 Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/195,698 Division US9714433B2 (en) 2007-06-15 2014-03-03 Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue

Publications (1)

Publication Number Publication Date
US20110039332A1 true US20110039332A1 (en) 2011-02-17

Family

ID=39253880

Family Applications (9)

Application Number Title Priority Date Filing Date
US12/663,840 Abandoned US20110039332A1 (en) 2007-06-15 2007-11-20 Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue
US12/157,967 Active 2029-09-20 US8211697B2 (en) 2007-06-15 2008-06-13 Induced pluripotent stem cells produced using reprogramming factors and a rho kinase inhibitor or a histone deacetylase inhibitor
US12/465,633 Abandoned US20090304646A1 (en) 2007-06-15 2009-05-13 Multipotent/Pluripotent Cells and Methods
US12/484,163 Active 2028-11-11 US8257941B2 (en) 2007-06-15 2009-06-12 Methods and platforms for drug discovery using induced pluripotent stem cells
US12/564,836 Abandoned US20100120069A1 (en) 2007-06-15 2009-09-22 Multipotent/pluripotent cells and methods
US12/580,216 Abandoned US20100105100A1 (en) 2007-06-15 2009-10-15 Multipotent/pluripotent cells and methods
US12/685,569 Abandoned US20100267135A1 (en) 2007-06-15 2010-01-11 Multipotent/pluripotent cells and methods
US12/709,379 Abandoned US20100240090A1 (en) 2007-06-15 2010-02-19 Methods and platforms for drug discovery
US14/195,698 Active 2028-06-24 US9714433B2 (en) 2007-06-15 2014-03-03 Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue

Family Applications After (8)

Application Number Title Priority Date Filing Date
US12/157,967 Active 2029-09-20 US8211697B2 (en) 2007-06-15 2008-06-13 Induced pluripotent stem cells produced using reprogramming factors and a rho kinase inhibitor or a histone deacetylase inhibitor
US12/465,633 Abandoned US20090304646A1 (en) 2007-06-15 2009-05-13 Multipotent/Pluripotent Cells and Methods
US12/484,163 Active 2028-11-11 US8257941B2 (en) 2007-06-15 2009-06-12 Methods and platforms for drug discovery using induced pluripotent stem cells
US12/564,836 Abandoned US20100120069A1 (en) 2007-06-15 2009-09-22 Multipotent/pluripotent cells and methods
US12/580,216 Abandoned US20100105100A1 (en) 2007-06-15 2009-10-15 Multipotent/pluripotent cells and methods
US12/685,569 Abandoned US20100267135A1 (en) 2007-06-15 2010-01-11 Multipotent/pluripotent cells and methods
US12/709,379 Abandoned US20100240090A1 (en) 2007-06-15 2010-02-19 Methods and platforms for drug discovery
US14/195,698 Active 2028-06-24 US9714433B2 (en) 2007-06-15 2014-03-03 Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue

Country Status (16)

Country Link
US (9) US20110039332A1 (es)
EP (4) EP2164952B1 (es)
JP (2) JP2008307007A (es)
KR (1) KR101657318B1 (es)
CN (1) CN102317448B (es)
AP (1) AP2010005102A0 (es)
AU (1) AU2008273817B2 (es)
CA (1) CA2690629A1 (es)
GB (2) GB2465291B (es)
HK (1) HK1143831A1 (es)
IL (1) IL202678A (es)
MX (1) MX2009013706A (es)
MY (1) MY159971A (es)
NZ (1) NZ582018A (es)
WO (3) WO2009006930A1 (es)
ZA (1) ZA200908904B (es)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090047263A1 (en) * 2005-12-13 2009-02-19 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20090068742A1 (en) * 2005-12-13 2009-03-12 Shinya Yamanaka Nuclear Reprogramming Factor
US20090191159A1 (en) * 2007-06-15 2009-07-30 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20090299763A1 (en) * 2007-06-15 2009-12-03 Izumi Bio, Inc. Methods of cell-based technologies
US20100216236A1 (en) * 2005-12-13 2010-08-26 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20100233804A1 (en) * 2008-03-17 2010-09-16 The Scripps Research Institute Generation of pluripotent stem cells using recombinant proteins
US20100279404A1 (en) * 2008-05-02 2010-11-04 Shinya Yamanaka Method of nuclear reprogramming
US20110044961A1 (en) * 2009-06-19 2011-02-24 Salk Institute For Biological Studies Generation of Induced Pluripotent Stem Cells from Cord Blood
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8906677B2 (en) 2008-12-17 2014-12-09 The Scripps Research Institute Generation and maintenance of stem cells
US9005968B2 (en) 2009-10-16 2015-04-14 The Scripps Research Institute Induction of pluripotent cells
US9018010B2 (en) 2009-11-12 2015-04-28 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US9040297B2 (en) 2006-08-02 2015-05-26 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
US9315779B2 (en) 2010-03-31 2016-04-19 The Scripps Research Institute Reprogramming cells
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
US9404079B2 (en) 2005-08-29 2016-08-02 Technion Research & Development Foundation Limited Media for culturing stem cells
US9732319B2 (en) 2010-12-22 2017-08-15 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
US10092600B2 (en) 2013-07-30 2018-10-09 Musculoskeletal Transplant Foundation Method of preparing an adipose tissue derived matrix
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
WO2019165320A1 (en) * 2018-02-22 2019-08-29 Celularity, Inc. Post partum tissue-derived induced pluripotent stem cells and uses thereof
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11268069B2 (en) 2014-03-04 2022-03-08 Fate Therapeutics, Inc. Reprogramming methods and cell culture platforms
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
US11473083B2 (en) 2015-12-21 2022-10-18 Novartis Ag Compositions and methods for decreasing tau expression

Families Citing this family (363)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
KR20130025953A (ko) * 2004-01-23 2013-03-12 어드밴스드 셀 테크놀로지, 인코포레이티드 망막 변성 질환 치료를 위한 개선된 양식
WO2007120811A2 (en) 2006-04-14 2007-10-25 Advanced Cell Technology, Inc. Hemangio-colony forming cells
CA2684242C (en) 2007-03-23 2019-11-12 Wisconsin Alumni Research Foundation Somatic cell reprogramming
US9029147B2 (en) 2007-06-15 2015-05-12 Massachusetts Institute Of Technology Methods and compositions for enhanced differentiation from embryonic stem cells
PT2209888T (pt) 2007-10-12 2020-01-17 Astellas Inst For Regenerative Medicine Métodos aperfeiçoados de produção de células rpe e composições de células rpe
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
AU2008286249B2 (en) 2007-12-10 2013-10-10 Kyoto University Efficient method for nuclear reprogramming
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090226912A1 (en) * 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
WO2009086425A1 (en) * 2007-12-28 2009-07-09 Fate Therapeutics, Inc. Methods for reprogramming cells to a pluripotent state and therapeutic applications related thereto
US20110014164A1 (en) * 2008-02-15 2011-01-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
CN102083963A (zh) * 2008-05-06 2011-06-01 先进细胞技术公司 血管瘤集落形成细胞和非移植血管瘤细胞
CN104328087A (zh) 2008-05-06 2015-02-04 先进细胞技术公司 用于制备衍生自多能干细胞的去核类红细胞的方法
EP2806037B1 (en) * 2008-05-13 2016-09-21 Gen-Probe Incorporated Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
JP2011522540A (ja) 2008-06-04 2011-08-04 セルラー ダイナミクス インターナショナル， インコーポレイテッド 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
EP2295538B1 (en) 2008-07-07 2015-10-21 Takara Bio Inc. Method for production of pluripotent stem cell
AU2008360135A1 (en) * 2008-07-31 2010-02-04 Gifu University Efficient method for establishing induced pluripotent stem cells
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
WO2010036923A1 (en) * 2008-09-25 2010-04-01 Salk Institute For Biological Studies Induced pluripotent stem cells and methods of use
EP2334804B1 (en) * 2008-10-07 2013-12-04 True North Therapeutics, Inc. Co-culture compositions and methods
CN105802917A (zh) * 2008-10-24 2016-07-27 威斯康星校友研究基金会 通过非病毒重编程获得的多潜能干细胞
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
CN101792776B (zh) * 2009-02-01 2013-12-11 中国人民解放军第二军医大学东方肝胆外科医院 一种高效诱导多能性干细胞的重组腺病毒载体、使用该载体的诱导方法及其用途
JP6189581B2 (ja) * 2009-02-20 2017-08-30 セルラー ダイナミクス インターナショナル， インコーポレイテッド 幹細胞の分化のための方法および組成物
US8951801B2 (en) * 2009-02-27 2015-02-10 Kyoto University Method for making IPS cells
US8372642B2 (en) 2009-02-27 2013-02-12 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
EP2414510A4 (en) * 2009-04-03 2013-04-17 Mclean Hospital Corp INDUCED PLURIPOTENT STEM CELLS
RU2399667C1 (ru) * 2009-04-10 2010-09-20 Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" Способ получения плюрипотентных клеток
WO2010119819A1 (ja) 2009-04-17 2010-10-21 国立大学法人東北大学 ヒト肺組織幹細胞の調製方法及びヒト肺胞上皮細胞への分化誘導方法
CN101580816B (zh) * 2009-04-23 2012-02-29 中国科学院广州生物医药与健康研究院 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法
JPWO2010131747A1 (ja) * 2009-05-15 2012-11-08 国立大学法人 東京大学 ウイルス産生細胞
EP3150701B1 (en) 2009-06-05 2018-10-03 FUJIFILM Cellular Dynamics, Inc. Reprogramming t cells and hematopoietic cells
JP5645197B2 (ja) * 2009-06-23 2014-12-24 学校法人日本大学 幹細胞の未分化状態を維持する新規方法
US20120178158A1 (en) * 2009-06-23 2012-07-12 The Scripps Research Institute Adult animals generated from induced pluripotent cells
JP2011004674A (ja) * 2009-06-26 2011-01-13 Fujitsu Ltd 誘導多能性幹細胞（ｉＰＳ細胞）の製造方法
WO2011005326A1 (en) 2009-07-09 2011-01-13 Massachusetts Institute Of Technology Methods and compositions for increased safety of stem cell-derived populations
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
WO2011019957A1 (en) * 2009-08-12 2011-02-17 University Of Southern California Method for formation of induced pluripotent stem cells
EP2468312A4 (en) 2009-08-19 2014-05-14 Univ Tohoku SHEET FOR KERATOPLASTIES
EP2467469A4 (en) * 2009-08-21 2013-07-24 Univ Leland Stanford Junior INCREASED EFFICIENCY OF INDUCED GENERATION OF PLURIPOTENTAL STEM CELLS FROM HUMAN BODIES
JP2013503198A (ja) * 2009-08-27 2013-01-31 シナプティック リサーチ，リミテッド ライアビリティ カンパニー 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系
WO2011032025A2 (en) * 2009-09-10 2011-03-17 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
CN102803476A (zh) * 2009-09-14 2012-11-28 程临钊 血细胞重编程产生多潜能干细胞和多功能干细胞
US9808504B2 (en) * 2009-09-22 2017-11-07 Yale University Immunogenic epitopes as targets for universal cancer vaccines
EP2483395B1 (en) 2009-09-30 2016-12-07 Agency For Science, Technology And Research A nuclear receptor and mutant thereof and the use of the same in the reprogramming of cells
EP2494032A4 (en) 2009-10-29 2013-06-05 Univ Mcmaster GENERATION OF INDUCED PLURIPOTENTER STEM CELLS AND FIBROBLAST PRECURSOR CELLS
SG10201407102QA (en) * 2009-10-30 2014-11-27 Univ North Carolina Multipotent stem cells from the extrahepatic billary tree and methods of isolating same
JP5898086B2 (ja) * 2009-11-04 2016-04-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 化学物質を用いるエピソームリプログラミング
EP2499241B8 (en) 2009-11-10 2018-02-21 The J. David Gladstone Institutes Methods of generating neural stem cells
IL301479A (en) 2009-11-17 2023-05-01 Astellas Inst For Regenerative Medicine Methods for preparing human RPE cells and pharmaceutical preparations of human RPE cells
US9988603B2 (en) 2009-12-04 2018-06-05 Stem Cell & Regenerative Medicine International Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
WO2011071118A1 (ja) 2009-12-09 2011-06-16 国立大学法人京都大学 ニトロビンを含む多能性幹細胞の心筋細胞への分化促進剤
CN102858958A (zh) * 2010-02-03 2013-01-02 日本国立癌症研究中心 诱导肝干细胞及其制造方法、以及该细胞的用途
US9228170B2 (en) * 2010-02-05 2016-01-05 Auckland Uniservices Limited Cell programming
EP2363502B1 (en) * 2010-03-04 2017-02-15 miacom Diagnostics GmbH Enhanced multiplex FISH
CN102190731B (zh) * 2010-03-09 2016-01-27 中国科学院上海生命科学研究院 用人工转录因子诱导产生多能干细胞
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
WO2011143415A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP5920725B2 (ja) * 2010-05-25 2016-05-18 国立研究開発法人国立がん研究センター 生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用
WO2011152798A1 (en) * 2010-06-02 2011-12-08 Agency For Science, Technology And Research Method for inducing pluripotency in human somatic cells with prdm14 or nfrkb
EP2397851B1 (fr) * 2010-06-21 2015-01-07 Centre d'Etude des Cellules Souches Méthode de sélection des modulateurs de la synthèse de mévalonate en utilisant des cellules dérivées de cellules pluripotentes humaines
US20120021445A1 (en) * 2010-06-29 2012-01-26 Hogan Kirk J Pluripotent Stem Cells for Drug Induced Myopathy and Malignant Hyperthermia
JP2012029684A (ja) * 2010-06-30 2012-02-16 Cell Aid Kenkyusho:Kk 細胞の製造方法
WO2012012708A1 (en) * 2010-07-22 2012-01-26 Regents Of The University Of Minnesota Induced pluripotent stem cells
EP2596119B8 (en) 2010-07-23 2021-06-02 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US9394523B2 (en) 2010-08-22 2016-07-19 Ramot At Tel-Aviv University Ltd. Induced pluripotent stem cells derived from human pancreatic beta cells
JP5930205B2 (ja) 2010-08-26 2016-06-08 国立大学法人京都大学 多能性幹細胞の心筋分化促進剤
US20130210146A1 (en) * 2010-08-26 2013-08-15 The Regents Of The University Of California Methods and Compositions for Generation of Induced Pluripotent Stem Cells By RNAA
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
US8068011B1 (en) 2010-08-27 2011-11-29 Q Street, LLC System and method for interactive user-directed interfacing between handheld devices and RFID media
WO2012031207A2 (en) 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
CA2812194C (en) * 2010-09-17 2022-12-13 President And Fellows Of Harvard College Functional genomics assay for characterizing pluripotent stem cell utility and safety
AU2011316830A1 (en) 2010-10-22 2013-05-02 Biotime Inc. Methods of modifying transcriptional regulatory networks in stem cells
JP2014513520A (ja) 2010-12-29 2014-06-05 シグマ−アルドリッチ・カンパニー、エルエルシー Ａｄｍｅおよび毒物学的プロセスに関与するタンパク質の乱された発現を有する細胞
US20120252122A1 (en) * 2011-01-05 2012-10-04 Sangamo Biosciences, Inc. Methods and compositions for increasing production of induced pluripotent stem cells (ipscs)
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
EP2665811B1 (en) 2011-01-19 2017-10-18 The Regents of The University of California Somatic cells with innate potential for pluripotency
WO2012112458A2 (en) * 2011-02-14 2012-08-23 The Regents Of The University Of California Compositions and methods for increasing reprogramming efficiency
US9228204B2 (en) 2011-02-14 2016-01-05 University Of Utah Research Foundation Constructs for making induced pluripotent stem cells
TWI445301B (zh) * 2011-03-03 2014-07-11 Realtek Semiconductor Corp 傳送／接收電路以及傳送／接收電路阻抗校正方法
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
US9187567B2 (en) 2011-05-18 2015-11-17 Parkinson's Institute Assay to determine LRRK2 activity in parkinson's disease
WO2012165287A1 (ja) 2011-05-27 2012-12-06 公立大学法人横浜市立大学 人工癌幹細胞の作製方法及びその分化誘導方法
WO2012174467A2 (en) * 2011-06-15 2012-12-20 Salk Institute For Biological Studies Cord blood-derived neurons by expression of sox2
US9395354B2 (en) 2011-07-21 2016-07-19 The Board Of Trustees Of The Leland Stanford Junior University Cardiomyocytes from induced pluripotent stem cells from patients and methods of use thereof
CN103703130A (zh) 2011-07-25 2014-04-02 国立大学法人京都大学 筛选诱导的多能干细胞的方法
US20130071931A1 (en) * 2011-08-02 2013-03-21 National Cancer Center Process for hepatic differentiation from induced hepatic stem cells, and induced hepatic progenitor cells differentiated thereby
EP2756092A4 (en) * 2011-09-16 2015-10-28 Giovanni Amabile METHOD FOR THE PRODUCTION OF CELLS, TISSUE AND ANTIBODIES
CN102329769B (zh) * 2011-09-28 2013-07-31 浙江大学 一种获得造血干细胞的方法
EP2766474B1 (en) 2011-10-14 2020-10-07 Children's Medical Center Corporation Inhibition and enhancement of reprogramming by chromatin modifying enzymes
WO2013058403A1 (ja) 2011-10-21 2013-04-25 国立大学法人京都大学 層流による多能性維持単一分散細胞培養法
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US20140329317A1 (en) 2011-11-25 2014-11-06 Kyoto University Method for culturing pluripotent stem cell
KR20230059838A (ko) 2011-11-30 2023-05-03 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
CN104080907A (zh) 2011-11-30 2014-10-01 日本国立癌症研究中心 诱导恶性干细胞
BR122020005735B1 (pt) 2011-12-01 2021-12-28 New York Stem Cell Foundation, Inc Sistema para a geração de células adultas diferenciadas a partir de células-tronco pluripotentes induzidas (ipscs)
US10428309B2 (en) 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
RU2624139C2 (ru) 2011-12-05 2017-06-30 Фэктор Байосайенс Инк. Способы и препараты для трансфекции клеток
KR101996343B1 (ko) 2012-01-27 2019-07-05 고쿠리츠 다이가쿠 호진 교토 다이가쿠 전능성 줄기세포의 심근분화 유도방법
EP2832851B1 (en) * 2012-03-28 2019-04-17 Quarrymen & Co. Inc. Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
US9447378B2 (en) 2012-04-27 2016-09-20 Massachusetts Institute Of Technology Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes
US10119150B2 (en) * 2012-05-13 2018-11-06 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US10155929B2 (en) * 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
DE202013012241U1 (de) 2012-05-25 2016-01-18 Emmanuelle Charpentier Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
CA2878163A1 (en) 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
US9175263B2 (en) * 2012-08-22 2015-11-03 Biotime, Inc. Methods and compositions for targeting progenitor cell lines
WO2014031085A1 (en) * 2012-08-24 2014-02-27 Agency For Science, Technology And Research The use of pdgf-bb in a method of enhancing the efficiency of reprogramming of a somatic cell to a pluripotent stem cell
WO2014055815A1 (en) * 2012-10-05 2014-04-10 Cincinnati Children's Hospital Medical Center Sebocyte cell culturing and methods of use
US20150313947A1 (en) * 2012-12-03 2015-11-05 Anthrogenesis Corporation Treatment of schizophrenia using amnion derived adherent cells
EP2934555B1 (en) 2012-12-21 2021-09-22 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells
BR112015015075A2 (pt) * 2012-12-24 2019-01-15 Univ Ramot agentes para tratar doenças genéticas resultantes de mutações sem sentido e métodos para identificar as mesmas.
JP6433902B2 (ja) * 2013-01-04 2018-12-05 国立大学法人京都大学 初期化幹細胞
US9709554B2 (en) 2013-01-31 2017-07-18 Rutgers, The State University Of New Jersey In vitro model of macrosteatotic (fatty) liver
JP6541577B2 (ja) 2013-02-06 2019-07-10 ユニバーシティー オブ ロチェスター ミエリン障害の治療のための誘導多能性細胞由来オリゴデンドロサイト前駆細胞
JP6156889B2 (ja) 2013-02-06 2017-07-05 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための不均質な骨髄細胞の亜集団を調製する方法
US20160002599A1 (en) 2013-02-08 2016-01-07 Kyoto University Production methods for megakaryocytes and platelets
US10160950B2 (en) 2013-03-01 2018-12-25 Wisconsin Alumni Research Foundation Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors
US20140248696A1 (en) * 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
EP2966163B1 (en) 2013-03-06 2018-01-17 Kyoto University Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
WO2014136519A1 (ja) 2013-03-08 2014-09-12 国立大学法人京都大学 Ｅｇｆ受容体阻害剤を含む多能性幹細胞の心筋分化促進剤
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
JP2016520291A (ja) 2013-03-14 2016-07-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｔｒｏでの内側神経節隆起前駆細胞の作製
US20160237400A1 (en) * 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
KR20160048029A (ko) * 2013-03-15 2016-05-03 마르쿠스 카레 토를레이프 라르손 제대혈 수집 및 세포의 분리를 위한 세포, 방법 및 장치
SG11201507829SA (en) 2013-03-21 2015-12-30 Univ Kyoto Pluripotent stem cell for neuronal differentiation induction
US10072242B2 (en) 2013-03-25 2018-09-11 Foundation For Biomedical Research And Innovation At Kobe Cell sorting method
CA2909230C (en) 2013-04-12 2021-06-15 Kyoto University Method for inducing alveolar epithelial progenitor cells
WO2014172616A2 (en) * 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
EP2998391B1 (en) 2013-05-14 2020-02-19 Kyoto University Efficient myocardial cell induction method
CN105247041B (zh) 2013-05-31 2018-04-20 爱心细胞有限公司 组入有水凝胶的层叠细胞膜片
AU2014274916B2 (en) 2013-06-05 2019-10-31 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
US10961531B2 (en) 2013-06-05 2021-03-30 Agex Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11085067B2 (en) 2013-06-10 2021-08-10 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
AU2014279065B2 (en) 2013-06-11 2020-04-09 Astellas Pharma Inc. Method for producing renal precursor cells, and drug containing renal precursor cells
KR102347062B1 (ko) * 2013-06-12 2022-01-03 가부시키가이샤 시세이도 Pdgf를 함유하는 ds 세포용 무혈청 배지
US9816070B2 (en) 2013-06-14 2017-11-14 Massachusetts Institute Of Technology Articles and methods for stem cell differentiation
WO2014210533A1 (en) * 2013-06-27 2014-12-31 The New York Stem Cell Foundation Improved systems and methods for producing stem cells and differentiated cells
WO2015006725A2 (en) 2013-07-12 2015-01-15 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
US20150024406A1 (en) * 2013-07-17 2015-01-22 Robin N. Coger-Simmons Increased aquaporin expression on cellular membrane to improve cryopreservation efficiency
EP3031905A4 (en) 2013-08-07 2017-04-26 Kyoto University Method for producing pancreatic hormone-producing cell
ES2615396T3 (es) 2013-08-22 2017-06-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Método para producir músculo cardiaco por ingeniería (EHM)
ES2721440T3 (es) 2013-09-05 2019-07-31 Univ Kyoto Nuevo método para inducir células precursoras neurales productoras de dopamina
WO2015037535A1 (ja) 2013-09-12 2015-03-19 株式会社カネカ 人工多能性幹細胞の分化誘導方法及び選別方法
JP6333830B2 (ja) 2013-09-13 2018-05-30 国立大学法人京都大学 多能性幹細胞の心筋分化を促進する化合物
EP3690032A1 (en) 2013-09-20 2020-08-05 Lonza Ltd. Methods for nuclear reprogramming of cells
SG10201802167TA (en) * 2013-09-20 2018-04-27 Repairon Gmbh A method to direct differentiation of pluripotent stem cells into functional heart muscle
CN104450609B (zh) * 2013-09-25 2017-07-14 深圳华大基因科技有限公司 一种分离和培养脐带间充质干细胞的方法
WO2015058117A1 (en) * 2013-10-18 2015-04-23 Icahn School Of Medicine At Mount Sinai Directed cardiomyocyte differentiation and ventricular specification of stem cells
EP3060649A4 (en) 2013-10-23 2017-07-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Reprogramming cardiomyocytes with one transcription factor
JP6635505B2 (ja) 2013-11-01 2020-01-29 国立大学法人京都大学 新規軟骨細胞誘導方法
WO2015069736A1 (en) 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
EP3071695A2 (en) 2013-11-18 2016-09-28 Crispr Therapeutics AG Crispr-cas system materials and methods
AU2014363032A1 (en) 2013-12-11 2016-06-09 Pfizer Limited Method for producing retinal pigment epithelial cells
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
US9512406B2 (en) 2013-12-20 2016-12-06 The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone Generating hepatocytes
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
RU2711942C2 (ru) * 2014-03-19 2020-01-23 Виселл Терапеутикс, Инк. Способы, относящиеся к плюрипотентным клеткам
US20170216838A1 (en) 2014-05-14 2017-08-03 University Of Limerick Microfluidic device with channel plates
JP6651218B2 (ja) 2014-05-30 2020-02-19 国立大学法人京都大学 低分子化合物を用いた多能性幹細胞の心筋分化誘導法
EP3786285A1 (en) * 2014-06-05 2021-03-03 Cedars-Sinai Medical Center A novel and efficient method for reprogramming immortalized lymphoblastoid cell lines to induced pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
JP7012432B2 (ja) 2014-07-14 2022-01-28 中外製薬株式会社 タンパク質のエピトープを同定するための方法
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
WO2016044681A1 (en) 2014-09-18 2016-03-24 North Carolina State University Mammalian lung spheroids and lung spheroid cells and uses thereof
US20170307596A1 (en) * 2014-10-15 2017-10-26 Coyne Ip Holdings, Llc Methods for Conducting Stimulus-Response Studies with Induced Pluripotent Stem Cells Derived from Perinatal Cells or Tissues
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
AU2015353853B2 (en) 2014-11-25 2020-10-15 President And Fellows Of Harvard College Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
WO2016088243A1 (ja) * 2014-12-05 2016-06-09 株式会社ニコン 判定装置、観察システム、観察方法、そのプログラム、細胞の製造方法、および細胞
JP7253692B2 (ja) 2014-12-26 2023-04-07 国立大学法人京都大学 肝細胞誘導方法
EP4406585A3 (en) 2015-02-13 2024-10-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2016131137A1 (en) 2015-02-17 2016-08-25 University Health Network Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes
EP3081638A1 (en) 2015-04-16 2016-10-19 Kyoto University Method for producing pseudo-islets
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
US10285388B2 (en) * 2015-05-29 2019-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
WO2017007784A1 (en) * 2015-07-06 2017-01-12 University Of Georgia Research Foundation Methods and compositions related to increased influenza virus production
EP3332020B1 (en) * 2015-08-07 2023-12-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Method of determining cellular protein homeostasis
CA2996582A1 (en) 2015-08-31 2017-03-09 I Peace, Inc. Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells
ES2895676T3 (es) 2015-09-01 2022-02-22 Ncardia B V Un método in vitro para diferenciar una población de células madre pluripotentes humanas en una población de células cardiomiocitas
AU2016339053A1 (en) 2015-09-24 2018-04-12 Crispr Therapeutics Ag Novel family of RNA-programmable endonucleases and their uses in genome editing and other applications
EP3360957A4 (en) * 2015-10-08 2019-03-13 Kaohsiung Medical University COMPOSITION FOR THE QUICK SEPARATION OF CELLS FROM FAT
CN108348556A (zh) * 2015-11-02 2018-07-31 欧瑞3恩公司 细胞周期阻滞提高产生诱导多能干细胞的效率
WO2017100683A1 (en) * 2015-12-09 2017-06-15 Stemgenics, Inc. Differential drug screening using pluripotent stem cells induced with functionalized nanoparticles
WO2017120443A1 (en) * 2016-01-07 2017-07-13 Cedars-Sinai Medical Center Method to identify key markers of human pluripotent cell-derived somatic cells that predict molecular similarity to in vivo target cells
WO2017123806A1 (en) 2016-01-12 2017-07-20 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
CA3013357A1 (en) 2016-02-01 2017-08-10 Cedars-Sinai Medical Center Systems and methods for growth of intestinal cells in microfluidic devices
WO2017143071A1 (en) 2016-02-18 2017-08-24 The Regents Of The University Of California Methods and compositions for gene editing in stem cells
WO2017159862A1 (ja) 2016-03-18 2017-09-21 国立大学法人京都大学 多能性幹細胞由来心筋細胞の凝集体の凍結方法
WO2017164746A1 (en) 2016-03-25 2017-09-28 Pluriomics B.V. In vivo method for differentiating human pluripotent stem cells into atrial cardiomyocytes
HUE056387T2 (hu) 2016-04-15 2022-02-28 Univ Kyoto Eljárás antigénspecifikus CD8-pozitív T-sejtek indukálására
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
US11352605B2 (en) 2016-05-12 2022-06-07 Erasmus University Medical Center Rotterdam Method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
WO2017216771A2 (en) 2016-06-17 2017-12-21 Genesis Technologies Limited Crispr-cas system, materials and methods
US11103537B2 (en) 2016-06-23 2021-08-31 Tithon Biotech Inc. Cells expressing parathyroid hormone 1 receptor and uses thereof
MX2018016055A (es) * 2016-06-23 2019-07-04 Tithon Biotech Inc Células que expresan receptor de hormona paratiroidea 1 y usos de las mismas.
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP7213799B2 (ja) 2016-10-10 2023-01-27 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 非細胞傷害性改変細胞およびその使用
US11542473B2 (en) 2016-10-21 2023-01-03 Amniotics Ab Methods and compositions for generating hematopoietic cells
US20200141921A1 (en) 2016-12-27 2020-05-07 Sumitomo Chemical Company, Limited Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells
EP3572502B1 (en) 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
WO2018140647A1 (en) 2017-01-25 2018-08-02 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
US12068059B2 (en) 2017-01-25 2024-08-20 Whitehead Institute For Biomedical Research Methods for building genomic networks and uses thereof
WO2018139548A1 (ja) 2017-01-26 2018-08-02 国立大学法人大阪大学 幹細胞の中胚葉系細胞への分化誘導用培地および中胚葉系細胞の製造方法
US10828330B2 (en) 2017-02-22 2020-11-10 IO Bioscience, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD FOR PRODUCING PANCREATIC ANALYZER CELLS
GB2574988B (en) * 2017-03-14 2022-09-14 Emulate Inc Neuromuscular junction: NMJ-on-chip
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
WO2018168829A1 (ja) 2017-03-14 2018-09-20 国立大学法人京都大学 多能性幹細胞からヘルパーｔ細胞を製造する方法
US11414648B2 (en) 2017-03-24 2022-08-16 Cedars-Sinai Medical Center Methods and compositions for production of fallopian tube epithelium
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP7457505B2 (ja) 2017-05-10 2024-03-28 ユニバーシティー オブ ロチェスター 神経精神障害を処置する方法
CA3064830A1 (en) 2017-05-25 2018-11-29 Kyoto University Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell
JPWO2018230588A1 (ja) 2017-06-14 2020-04-16 武田薬品工業株式会社 細胞封入デバイス
JP6736772B2 (ja) 2017-06-19 2020-08-05 公益財団法人神戸医療産業都市推進機構 多能性幹細胞の分化能の予測方法及びそのための試薬
JP6758631B2 (ja) 2017-06-19 2020-09-23 国立大学法人大阪大学 角膜内皮細胞マーカー及びその利用
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
JP7140400B2 (ja) 2017-10-17 2022-09-21 国立大学法人京都大学 多能性幹細胞から人工神経筋接合部を得る方法
EP3707256A1 (en) 2017-11-09 2020-09-16 CRISPR Therapeutics AG Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
IL305391B2 (en) 2017-11-15 2024-09-01 Vertex Pharma Preparations for the production of islet cells and methods of use
CA3083253A1 (en) 2017-11-30 2019-06-06 Kyoto University Method for culture of cells
KR102137884B1 (ko) * 2017-12-12 2020-07-24 순천향대학교 산학협력단 타우로우루소디옥시콜린산을 포함하는 고효율 세포전환용 배지 첨가제
KR102137883B1 (ko) * 2017-12-12 2020-07-24 순천향대학교 산학협력단 페닐부틸산나트륨을 포함하는 고효율 세포전환용 배지 첨가제
CA3084825A1 (en) 2017-12-14 2019-06-20 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and their use in genome editing and other applications
US11624049B2 (en) 2017-12-22 2023-04-11 Orizuru Therapeutics, Inc. Cell culturing apparatus, culture solution aspirator, and cell culturing method
JP7550648B2 (ja) 2018-03-19 2024-09-13 クリスパー セラピューティクス アーゲー 新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
TW201945536A (zh) 2018-03-19 2019-12-01 國立大學法人京都大學 水凝膠膠囊
KR102209108B1 (ko) * 2018-03-27 2021-01-28 국립암센터 Oct4 기능 저해용 펩티드를 포함하는 줄기세포성 억제용 조성물
CN111918866B (zh) 2018-03-30 2023-07-04 千纸鹤治疗公司 杂环化合物
CN111971392A (zh) 2018-03-30 2020-11-20 国立大学法人京都大学 细胞的制造方法
EP3778869A4 (en) 2018-03-30 2021-12-08 Kyoto University CARDIOMYOCYTE MATURATION PROMOTER
WO2019195800A1 (en) 2018-04-06 2019-10-10 Cedars-Sinai Medical Center Novel differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
TW201945364A (zh) 2018-04-23 2019-12-01 國立大學法人京都大學 增殖抑制劑
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
CN112513257A (zh) * 2018-06-14 2021-03-16 中央研究院 产生诱导式少突胶质谱系细胞的方法及使用所述细胞的治疗
US20210260002A1 (en) 2018-06-18 2021-08-26 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
EP3810184A2 (en) 2018-06-21 2021-04-28 University of Rochester Methods of treating or inhibiting onset of huntington's disease
WO2020013315A1 (ja) 2018-07-13 2020-01-16 国立大学法人京都大学 γδＴ細胞の製造方法
EP3824912A4 (en) 2018-07-19 2022-04-20 Kyoto University PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE
JP7357369B2 (ja) 2018-07-23 2023-10-06 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
US20210292708A1 (en) 2018-08-03 2021-09-23 Kyoto University Cell production method
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated ISLE DIFFERENTIATION DERIVED FROM STEM CELLS
US20210301260A1 (en) 2018-08-10 2021-09-30 Kyoto University Method for producing cd3-positive cell
US20220145329A1 (en) 2018-08-10 2022-05-12 Kyoto University Method for transfection into cardiomyocytes using cationic lipid
EP3842525A4 (en) 2018-08-22 2022-07-27 Kyoto University PROCEDURE FOR GENERATING A NERVE PROGENIOR CELL OF THE INTESTINAL TRACT
SG11202101930XA (en) 2018-08-31 2021-03-30 Noile Immune Biotech Inc Car-expressing t cells and car expression vector
US20210353686A1 (en) 2018-09-19 2021-11-18 Takeda Pharmaceutical Company Limited Insulin-producing cells
EP3868869A4 (en) 2018-10-15 2022-08-03 Public University Corporation Yokohama City University NUTRITIONAL COMPOSITION
WO2020116606A1 (ja) 2018-12-06 2020-06-11 キリンホールディングス株式会社 Ｔ細胞又はｎｋ細胞の製造方法、ｔ細胞又はｎｋ細胞の培養用培地、ｔ細胞又はｎｋ細胞の培養方法、未分化ｔ細胞の未分化状態を維持する方法及びｔ細胞又はｎｋ細胞の増殖促進剤
AU2019396450A1 (en) 2018-12-11 2021-06-24 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
WO2020131632A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
SG11202106673XA (en) * 2018-12-21 2021-07-29 I Peace Inc Health risk information management device, health risk information management method, and program
WO2020130147A1 (ja) 2018-12-21 2020-06-25 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
EP3903884A4 (en) 2018-12-26 2023-01-25 Kirin Holdings Kabushiki Kaisha MODIFIED TCR AND MANUFACTURING PROCESS THEREOF
JP7542822B2 (ja) 2018-12-27 2024-09-02 国立大学法人京都大学 Ｔ細胞受容体の改変体
WO2020158914A1 (ja) 2019-02-01 2020-08-06 国立大学法人京都大学 細胞の検出方法
US20230057355A1 (en) 2019-02-13 2023-02-23 University Of Rochester Gene networks that mediate remyelination of the human brain
MX2021010559A (es) 2019-03-07 2021-12-15 Univ California Polipéptidos efectores de crispr-cas y métodos de uso de estos.
WO2020209959A1 (en) 2019-03-08 2020-10-15 Crispr Therapeutics Ag Nucleobase-editing fusion protein systems, compositions, and uses thereof
EP3937963A2 (en) 2019-03-12 2022-01-19 CRISPR Therapeutics AG Novel high fidelity rna-programmable endonuclease systems and uses thereof
KR20210144793A (ko) 2019-03-29 2021-11-30 고리츠다이가쿠호진 요코하마시리츠다이가쿠 스크리닝 방법 및 독성 평가 방법
TW202104590A (zh) 2019-04-10 2021-02-01 國立大學法人京都大學 類生體組織結構體的製造方法
WO2020225606A1 (en) 2019-05-08 2020-11-12 Crispr Therapeutics Ag Crispr/cas all-in-two vector systems for treatment of dmd
JPWO2020235319A1 (es) 2019-05-20 2020-11-26
US20220313733A1 (en) 2019-06-11 2022-10-06 Kyoto University Method for producing renal interstitial cell
EP3990624A1 (en) 2019-06-25 2022-05-04 Vertex Pharmaceuticals Incorporated Enhanced differentiation of beta cells
CN110257334A (zh) * 2019-07-24 2019-09-20 安徽科门生物科技有限公司 一种神经干细胞培养基以及培养方法
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
WO2021030424A1 (en) 2019-08-13 2021-02-18 Semma Therapeutics, Inc. Pancreatic differentiation
JP7541748B2 (ja) 2019-08-20 2024-08-29 オリヅルセラピューティクス株式会社 心筋細胞の富化方法
US20220372444A1 (en) 2019-10-18 2022-11-24 Amniotics Ab Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
JPWO2021079874A1 (es) 2019-10-21 2021-04-29
TWI769410B (zh) * 2019-10-28 2022-07-01 中國醫藥大學 新穎誘導性多能幹細胞(ipscs)及其應用
US11760980B2 (en) 2019-10-28 2023-09-19 China Medical University Induced pluripotent stem cells (IPSCS) and applications thereof
WO2021085576A1 (ja) 2019-11-01 2021-05-06 国立大学法人京都大学 Ｔ細胞の製造方法
US20230000915A1 (en) 2019-11-25 2023-01-05 Kyoto University T-cell master cell bank
JP7058431B2 (ja) 2019-12-12 2022-04-22 国立大学法人千葉大学 巨核球および血小板を含む凍結乾燥製剤
IL293946A (en) * 2019-12-18 2022-08-01 Editas Medicine Inc Transgenic cells for therapy
EP4087914A1 (en) 2020-01-09 2022-11-16 Herophilus, Inc. Methods and compositions of pro-organ formation on particle substrates and uses thereof
IL295668A (en) * 2020-02-16 2022-10-01 Genetikaplus Ltd Methods for medical prognostics
US20210292713A1 (en) 2020-02-28 2021-09-23 Millennium Pharmaceuticals, Inc. Method for producing natural killer cells from pluripotent stem cells
CA3175573A1 (en) 2020-03-19 2021-09-23 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
JPWO2021187602A1 (es) 2020-03-19 2021-09-23
US20230159891A1 (en) 2020-03-31 2023-05-25 Kyoto University T cell progenitor production method
CN115551998A (zh) 2020-05-26 2022-12-30 希里欧斯株式会社 低免疫原性细胞
JPWO2021241668A1 (es) 2020-05-28 2021-12-02
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
US20230235319A1 (en) 2020-06-12 2023-07-27 Bayer Aktiengesellschaft Crispr-cas12a directed random mutagenesis agents and methods
JPWO2021256522A1 (es) 2020-06-17 2021-12-23
JP7429294B2 (ja) 2020-07-13 2024-02-07 国立大学法人京都大学 骨格筋前駆細胞及びその精製方法、筋原性疾患を治療するための組成物、並びに骨格筋前駆細胞を含む細胞群の製造方法
JPWO2022019152A1 (es) 2020-07-20 2022-01-27
CN116323917A (zh) 2020-08-18 2023-06-23 国立大学法人京都大学 人原始生殖细胞/人原始生殖细胞样细胞的维持扩增方法
WO2022107877A1 (ja) 2020-11-20 2022-05-27 オリヅルセラピューティクス株式会社 成熟化剤
CA3208794A1 (en) 2021-02-09 2022-08-18 Orizuru Therapeutics, Inc. Maturation agent
USD969942S1 (en) * 2021-03-03 2022-11-15 Amber Puchlov Exercise device
EP4306633A1 (en) 2021-03-09 2024-01-17 National University Corporation Tokyo Medical and Dental University Cell cluster production method
US20240182858A1 (en) 2021-03-17 2024-06-06 Astellas Pharma Inc. Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein
CN113106059B (zh) * 2021-04-07 2023-08-15 清华大学深圳国际研究生院 一种高迁徙间充质干细胞及其制备方法和应用
WO2022215718A1 (ja) 2021-04-08 2022-10-13 武田薬品工業株式会社 Ｔ細胞活性化方法
EP4332215A1 (en) 2021-04-28 2024-03-06 National University Corporation Tokyo Medical and Dental University Method for producing cells
WO2022230977A1 (ja) 2021-04-30 2022-11-03 国立研究開発法人理化学研究所 網膜色素上皮細胞のひも状凝集体、それを製造するためのデバイスおよび製造方法、ならびに該ひも状凝集体を含有する治療薬
WO2022236187A1 (en) 2021-05-07 2022-11-10 Children's Hospital Los Angeles Methods for making stem cell-derived enteric neural crest cells and their use in enteric neuropathy treatment
WO2022250631A2 (en) * 2021-05-25 2022-12-01 T.C. Ankara Universitesi Rektorlugu Disease model of induced pluripotent stem cell (ipsc)-derived type 2 diabetes mellitus, associated with coronary artery disease
JPWO2022255489A1 (es) 2021-06-04 2022-12-08
WO2022259721A1 (ja) 2021-06-10 2022-12-15 味の素株式会社 間葉系幹細胞の製造方法
US20240141312A1 (en) 2021-06-11 2024-05-02 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
JP2024523332A (ja) 2021-06-15 2024-06-28 武田薬品工業株式会社 多能性幹細胞からナチュラルキラー細胞を産生するための方法
JPWO2023286834A1 (es) 2021-07-15 2023-01-19
WO2023286832A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞の製造方法
EP4374914A1 (en) 2021-07-21 2024-05-29 Kyoto University Method for producing retinal tissue
WO2023017848A1 (ja) 2021-08-11 2023-02-16 国立大学法人京都大学 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
CN118056007A (zh) 2021-09-27 2024-05-17 国立大学法人京都大学 用于生产t细胞的方法
AU2022371414A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
US20230292719A1 (en) 2021-10-20 2023-09-21 University Of Rochester Humanized chimeras for the prospective assessment of cell addition and replacement therapies
EP4419654A1 (en) 2021-10-20 2024-08-28 University of Rochester Method for rejuvenating glial progenitor cells and rejuvenated glial progenitor cells per se
AU2022371442A1 (en) 2021-10-21 2024-04-18 Vertex Pharmaceuticals Incorporated Hypoimmune cells
IL311636A (en) 2021-11-01 2024-05-01 Vertex Pharma Differentiation of stem cell-derived pancreatic islets
US20230270818A1 (en) 2021-11-02 2023-08-31 University Of Rochester Tcf7l2 mediated remyelination in the brain
CA3238206A1 (en) 2021-11-11 2023-05-19 Healios K.K. Gene-modified pluripotent stem cell, immunocompetent cell derived therefrom, method for producing said cells, and use thereof
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023150557A1 (en) 2022-02-01 2023-08-10 University Of Rochester Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods
JPWO2023149555A1 (es) 2022-02-04 2023-08-10
CN118679244A (zh) 2022-02-09 2024-09-20 住友制药株式会社 判定培养液中的细胞在由多能干细胞向中脑底板区域的神经系统细胞的分化中的分化能力的方法
WO2023167986A1 (en) 2022-03-02 2023-09-07 Lineage Cell Therapeutics, Inc. Methods and compositions for treating hearing loss
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss
WO2023215455A1 (en) 2022-05-05 2023-11-09 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023247532A1 (en) 2022-06-21 2023-12-28 Institut National de la Santé et de la Recherche Médicale A method for producing a bioengineered mammal induced pluripotent stem cell-derived cardiac organoid
WO2024129743A2 (en) 2022-12-13 2024-06-20 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells
WO2024167814A1 (en) 2023-02-06 2024-08-15 Bluerock Therapeutics Lp Degron fusion proteins and methods of production and use thereof
WO2024190718A1 (ja) * 2023-03-14 2024-09-19 積水化学工業株式会社 人工多能性幹細胞の製造方法

Citations (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5225348A (en) * 1989-03-14 1993-07-06 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324645A (en) * 1989-12-14 1994-06-28 Ajinomoto Co., Inc. Highly retrovirus-producing DNA construct and cell line
US5449614A (en) * 1988-09-01 1995-09-12 Whitehead Institue For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5744320A (en) * 1995-06-07 1998-04-28 Promega Corporation Quenching reagents and assays for enzyme-mediated luminescence
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5830725A (en) * 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US5858740A (en) * 1993-06-11 1999-01-12 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6025192A (en) * 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US6203975B1 (en) * 1994-10-28 2001-03-20 The Trustees Of The University Of Pennsylvania Adenovirus and method of use thereof
US6255071B1 (en) * 1996-09-20 2001-07-03 Cold Spring Harbor Laboratory Mammalian viral vectors and their uses
US6365352B1 (en) * 1997-08-22 2002-04-02 Yale University Process to study changes in gene expression in granulocytic cells
US6395546B1 (en) * 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
US20020090722A1 (en) * 2000-06-15 2002-07-11 Tanja Dominko Pluripotent mammalian cells
US6451595B1 (en) * 1998-06-26 2002-09-17 Viromed Limited High efficiency retroviral vectors that contain none of viral coding sequences
US20030003574A1 (en) * 2000-01-24 2003-01-02 Jean Toma Multipotent stem cells from peripheral tissues and uses thereof
US6521453B1 (en) * 1999-01-19 2003-02-18 Maxygen, Inc. Oligonucloetide mediated nucleic acid recombination
US6521455B2 (en) * 1995-07-28 2003-02-18 Marie Curie Cancer Care Nucleic acid molecule encoding a transport protein
US20030044976A1 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
US6605275B1 (en) * 1987-11-12 2003-08-12 Pharmastem Therapeutics, Inc. Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US20030161817A1 (en) * 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US20040048297A1 (en) * 2002-07-30 2004-03-11 Gene Logic, Inc. Nucleic acid detection assay control genes
US20040137460A1 (en) * 2001-05-31 2004-07-15 Shinya Yamanaka Genes with es cell-specific expression
US6773920B1 (en) * 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6841535B2 (en) * 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use
US20050019801A1 (en) * 2003-06-04 2005-01-27 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
US20050026133A1 (en) * 2002-01-31 2005-02-03 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
US6872528B2 (en) * 1996-07-16 2005-03-29 Universite Pierre Et Marie Curie Highly productive packaging lines
US6875578B2 (en) * 1997-02-27 2005-04-05 Cellomics, Inc. System for cell-based screening
US20050079606A1 (en) * 2001-09-20 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. Pluripotent stem cells originating in skeletal muscle intestinal tissue
US6881825B1 (en) * 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US20050110830A1 (en) * 2003-11-26 2005-05-26 Masayuki Tashiro Ejection device, manufacturing device of color filter substrate, manufacturing device of electro-luminescent display device, manufacturing device of plasma display device, and ejection method
US20050130144A1 (en) * 2001-09-21 2005-06-16 Norio Nakatsuji Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
US6910434B2 (en) * 2000-08-31 2005-06-28 Edwin Lundgren Control device for steering kite on a boat
US6995009B1 (en) * 1999-06-01 2006-02-07 Chugai Seiyaku Kabushiki Kaisha Packaging cell
US20060030041A1 (en) * 1999-08-05 2006-02-09 Regents Of The University Of Minnesota Multipotent adult stem cells and methods for isolation
US7029913B2 (en) * 1995-01-20 2006-04-18 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US7030292B2 (en) * 2001-01-02 2006-04-18 Stemron, Inc. Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
US20060084172A1 (en) * 2001-12-10 2006-04-20 Julius-Maximilians-Unversitat Wurzburg Method for producing stem cells with increased developmental potential
US20060088599A1 (en) * 2004-08-02 2006-04-27 Prasad Paras N Amino functionalized ORMOSIL nanoparticles as delivery vehicles
US20060095319A1 (en) * 2004-10-29 2006-05-04 Cardwell Carlzo B Marketing and compensation method
US7070994B2 (en) * 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US20070033061A1 (en) * 2005-04-05 2007-02-08 Achaogen, Inc. Business methods for commercializing antimicrobial and cytotoxic compounds
US20070053884A1 (en) * 2003-05-16 2007-03-08 Kyowa Hakko Kogyo Co., Ltd Novel adult tissue-derived stem cell and use thereof
US20070155013A1 (en) * 2004-03-23 2007-07-05 Toshihiro Akaike Pluripotent stem cell growing method
US20070202592A1 (en) * 2004-07-08 2007-08-30 Yasuo Kitagawa Pluripotent Cells Distributed Ubiquitously In Animal Tissue, Which Proliferate Selectively In Lower-Serum Culture
US20080003560A1 (en) * 2001-09-21 2008-01-03 Reprocell Inc. Tailor-made pluripotent stem cell and use of the same
US20080085555A1 (en) * 2005-02-28 2008-04-10 Takayuki Asahara Method For In Vitro Amplification Of Adult Stem Cells
US20080132803A1 (en) * 2006-11-30 2008-06-05 Hyman Friedlander Method and system for doing business by mining the placental-chord complex
US20080171385A1 (en) * 2007-01-17 2008-07-17 Veit Bergendahl Culture of stem cells
US20080171358A1 (en) * 2004-06-01 2008-07-17 Jacques Perrault Expression System
US20080206865A1 (en) * 2001-10-03 2008-08-28 Su-Chun Zhang Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US20080233610A1 (en) * 2007-03-23 2008-09-25 Thomson James A Somatic cell reprogramming
US7439064B2 (en) * 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US20090047263A1 (en) * 2005-12-13 2009-02-19 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20090068742A1 (en) * 2005-12-13 2009-03-12 Shinya Yamanaka Nuclear Reprogramming Factor
US20090191159A1 (en) * 2007-06-15 2009-07-30 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US20090191171A1 (en) * 2008-01-18 2009-07-30 Yupo Ma Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous Recombination
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20100003757A1 (en) * 2008-06-04 2010-01-07 Amanda Mack Methods for the production of ips cells using non-viral approach
US20100021437A1 (en) * 2008-04-07 2010-01-28 The McLean Hospital Corporation Whitehead Institute for Biomedical Research Neural stem cells derived from induced pluripotent stem cells
US20100062534A1 (en) * 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
US20100075421A1 (en) * 2007-12-10 2010-03-25 Kyoto University Efficient method for nuclear reprogramming
US20100093090A1 (en) * 2008-04-03 2010-04-15 Peking University Method and kit for efficient reprogramming of somatic cells
US20100144031A1 (en) * 2003-11-26 2010-06-10 Rudolf Jaenisch Methods for reprogramming somatic cells
US20100184051A1 (en) * 2007-05-30 2010-07-22 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
US20100184227A1 (en) * 2008-10-24 2010-07-22 James Thomson Pluripotent stem cells obtained by non-viral reprogramming
US20100216236A1 (en) * 2005-12-13 2010-08-26 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20100233804A1 (en) * 2008-03-17 2010-09-16 The Scripps Research Institute Generation of pluripotent stem cells using recombinant proteins

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4864719A (en) * 1987-04-24 1989-09-12 Amp Incorporated Tool for removing electrical contacts
JP2886547B2 (ja) 1988-07-26 1999-04-26 協和醗酵工業株式会社 ノイラミニダーゼの製造法
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5534423A (en) 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
JP4216350B2 (ja) 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
CA2231251A1 (en) 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US6153745A (en) 1995-09-22 2000-11-28 Amersham Pharmacia Biotech Uk Limited Relating to mutagenesis of nucleic acids
EP1717315A3 (en) 1997-04-16 2007-06-20 Amgen Inc. Osteoprotegerin binding proteins and receptors
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US20020174013A1 (en) 1998-04-17 2002-11-21 Viztec Inc., A Florida Corporation Chip card advertising method and system
GB9809178D0 (en) 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
FR2779445B1 (fr) 1998-06-08 2000-08-11 Univ Nantes Kit d'encapsidation
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
CA2344653A1 (en) 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US6485959B1 (en) 1998-10-07 2002-11-26 Cedars Sinai Medical Center Cell preconditioning and cryopresevation medium
AU6339399A (en) * 1998-10-16 2000-05-08 Novartis Ag Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
JP2002529070A (ja) 1998-11-09 2002-09-10 モナシュ・ユニヴァーシティ 胚性幹細胞
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
US6312949B1 (en) 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
WO2001021767A2 (en) * 1999-09-24 2001-03-29 Morphogen Pharmaceuticals, Inc. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
CN100580079C (zh) 2000-05-17 2010-01-13 杰龙公司 神经祖细胞群体
DE10031179A1 (de) 2000-06-27 2002-01-31 Amaxa Gmbh Verfahren zur Einbringung von Nukleinsäuren und anderen biologisch aktiven Molekülen in den Kern höherer eukaryontischer Zellen mit Hilfe elektrischen Stroms
JP2002065261A (ja) 2000-08-30 2002-03-05 Mitsubishi Kasei Institute Of Life Sciences 生殖細胞の取得方法
US20020127715A1 (en) 2000-11-27 2002-09-12 Nissim Benvenisty Transfection of human embryonic stem cells
US20080268054A1 (en) 2000-12-04 2008-10-30 Eugene Bell Dermal derived human stem cells and compositions and methods thereof
US20020142397A1 (en) 2000-12-22 2002-10-03 Philippe Collas Methods for altering cell fate
JP2003009854A (ja) 2001-04-09 2003-01-14 Kyowa Hakko Kogyo Co Ltd エンブリオイドボディ形成方法及びその用途
DE10291734D2 (de) 2001-04-23 2004-05-27 Lorbach Elke Pufferlösung für die Elektroporation und Verfahren umfassend die Verwendung derselben
DE10119901A1 (de) 2001-04-23 2002-10-24 Amaxa Gmbh Schaltungsanordnung zur Einbringung von Nukleinsäuren und anderen biologisch aktiven Molekülen in den Kern höherer eukaryontischer Zellen mit Hilfe elektrischen Stroms
KR20040097200A (ko) 2002-03-26 2004-11-17 김소운 3차원 안경 시뮬레이션 시스템 및 방법
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
JP3736517B2 (ja) 2002-11-13 2006-01-18 学校法人近畿大学 体細胞核初期化因子
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US7462602B2 (en) 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US9567591B2 (en) 2003-05-15 2017-02-14 Mello Biotechnology, Inc. Generation of human embryonic stem-like cells using intronic RNA
US7498024B2 (en) 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2005033297A1 (en) 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
JP2005095027A (ja) 2003-09-22 2005-04-14 Reprocell Inc 細胞の未分化状態マーカープロモーターおよびその利用
WO2005035741A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. ゲノムが改変された細胞
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
CA2549158A1 (en) 2003-12-01 2005-06-16 Technion Research And Development Foundation Ltd. Methods of generating stem cells and embryonic bodies carrying disease-causing mutations and methods of using same for studying genetic disorders
JP4340736B2 (ja) 2004-01-15 2009-10-07 国立大学法人福井大学 レポーター遺伝子を組み込んだベクター
WO2005080598A1 (ja) 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
WO2006084229A2 (en) 2004-07-15 2006-08-10 Primegen Biotech, Llc Use of nuclear material to therapeutically reprogram differentiated cells
FR2873175B1 (fr) * 2004-07-16 2006-10-20 Poclain Hydraulics Ind Soc Par Circuit hydraulique comprenant un selecteur multifonction
EP1811023A4 (en) 2004-09-29 2009-04-29 Dainippon Sumitomo Pharma Co SPECIFICALLY EXPRESSED IN ES CELLS AND USE THEREOF
WO2006083331A2 (en) 2004-10-08 2006-08-10 Intronn, Inc Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
FR2885536B1 (fr) * 2005-05-12 2007-07-27 Roquette Freres Composition a base d'ethers de dianhydrohexitol pour le traitement d'une matiere autre que le corps humain
WO2007026255A2 (en) 2005-06-22 2007-03-08 Universitetet I Oslo Dedifferentiated cells and methods of making and using dedifferentiated cells
CN101595228A (zh) 2005-07-21 2009-12-02 艾博特公司 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
CA2659945C (en) 2005-08-03 2014-12-16 Advanced Cell Technology, Inc. Improved methods of reprogramming animal somatic cells
JP2007117081A (ja) * 2005-09-30 2007-05-17 Institute Of Physical & Chemical Research 核移植卵子の作製方法
AU2006313518A1 (en) 2005-11-11 2007-05-18 The University Court Of University Of Edinburgh Reprogramming and genetic modification of cells
JP2009528050A (ja) 2006-02-27 2009-08-06 イムジェン カンパニー リミテッド Ｂｍｉ−１を用いた星状細胞の神経幹細胞への脱分化
US20090252711A1 (en) * 2006-05-11 2009-10-08 Andrew Craig Boquest Stem Cells And Methods Of Making And Using Stem Cells
WO2008030610A2 (en) 2006-09-08 2008-03-13 Michigan State University Human transcriptome corresponding to human oocytes and use of said genes or the corresponding polypeptides to trans-differentiate somatic cells
JP2008099662A (ja) * 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
WO2008105566A1 (en) 2007-02-27 2008-09-04 Korea Stem Cell Bank System for providing stem cell services using internet and method thereof
EP2132225A4 (en) 2007-02-27 2010-06-09 Procell Therapeutics Inc COMBINED USE OF NANOG AND OCT4 PERMEABLE TO CELLS TO INCREASE SELF-RENEWAL AND DELETE DIFFERENTIATION OF STEM CELLS
EP2145000A4 (en) 2007-04-07 2010-05-05 Whitehead Biomedical Inst REPROGRAMMING SOMATIC CELLS
JP2010528613A (ja) 2007-05-29 2010-08-26 クリストファー ビー． リード， 多能細胞集団を産生する方法およびその使用
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US20120282229A1 (en) * 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
US20090191160A1 (en) 2007-08-10 2009-07-30 University Of Dayton Methods of producing pluripotent stem-like cells
ES2589122T3 (es) * 2007-08-31 2016-11-10 Whitehead Institute For Biomedical Research Estimulación de la ruta de la Wnt en la reprogramación de células somáticas
CA2660123C (en) * 2007-10-31 2017-05-09 Kyoto University Nuclear reprogramming method
WO2009061442A1 (en) * 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
WO2009067563A1 (en) 2007-11-19 2009-05-28 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
US9683232B2 (en) * 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
KR101481164B1 (ko) 2008-01-30 2015-01-09 주식회사 미래셀바이오 체세포 유래 다능성 줄기세포의 제조 방법
US20110014164A1 (en) 2008-02-15 2011-01-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2009115295A1 (en) 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CN101250502A (zh) 2008-04-01 2008-08-27 中国科学院上海生命科学研究院 一种诱导的多潜能干细胞的制备方法
SG10201400329YA (en) 2008-05-02 2014-05-29 Univ Kyoto Method of nuclear reprogramming
EP2128245A1 (en) 2008-05-27 2009-12-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Generation of induced pluripotent stem (iPS) cells
AU2008360135A1 (en) 2008-07-31 2010-02-04 Gifu University Efficient method for establishing induced pluripotent stem cells
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
JP4992952B2 (ja) 2009-11-02 2012-08-08 住友電気工業株式会社 交通信号制御分析装置

Patent Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US6605275B1 (en) * 1987-11-12 2003-08-12 Pharmastem Therapeutics, Inc. Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US5716832A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Packaging cells
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US7070994B2 (en) * 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5955331A (en) * 1988-09-01 1999-09-21 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5449614A (en) * 1988-09-01 1995-09-12 Whitehead Institue For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5225348A (en) * 1989-03-14 1993-07-06 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5324645A (en) * 1989-12-14 1994-06-28 Ajinomoto Co., Inc. Highly retrovirus-producing DNA construct and cell line
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5858740A (en) * 1993-06-11 1999-01-12 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6203975B1 (en) * 1994-10-28 2001-03-20 The Trustees Of The University Of Pennsylvania Adenovirus and method of use thereof
US7029913B2 (en) * 1995-01-20 2006-04-18 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5830725A (en) * 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US5744320A (en) * 1995-06-07 1998-04-28 Promega Corporation Quenching reagents and assays for enzyme-mediated luminescence
US6521455B2 (en) * 1995-07-28 2003-02-18 Marie Curie Cancer Care Nucleic acid molecule encoding a transport protein
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6017761A (en) * 1995-12-15 2000-01-25 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6872528B2 (en) * 1996-07-16 2005-03-29 Universite Pierre Et Marie Curie Highly productive packaging lines
US6255071B1 (en) * 1996-09-20 2001-07-03 Cold Spring Harbor Laboratory Mammalian viral vectors and their uses
US6025192A (en) * 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
US6251398B1 (en) * 1997-01-23 2001-06-26 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6875578B2 (en) * 1997-02-27 2005-04-05 Cellomics, Inc. System for cell-based screening
US6365352B1 (en) * 1997-08-22 2002-04-02 Yale University Process to study changes in gene expression in granulocytic cells
US6451595B1 (en) * 1998-06-26 2002-09-17 Viromed Limited High efficiency retroviral vectors that contain none of viral coding sequences
US6521453B1 (en) * 1999-01-19 2003-02-18 Maxygen, Inc. Oligonucloetide mediated nucleic acid recombination
US6773920B1 (en) * 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6995009B1 (en) * 1999-06-01 2006-02-07 Chugai Seiyaku Kabushiki Kaisha Packaging cell
US20060030041A1 (en) * 1999-08-05 2006-02-09 Regents Of The University Of Minnesota Multipotent adult stem cells and methods for isolation
US6881825B1 (en) * 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US20030003574A1 (en) * 2000-01-24 2003-01-02 Jean Toma Multipotent stem cells from peripheral tissues and uses thereof
US6395546B1 (en) * 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
US7439064B2 (en) * 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US20020090722A1 (en) * 2000-06-15 2002-07-11 Tanja Dominko Pluripotent mammalian cells
US6841535B2 (en) * 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use
US6910434B2 (en) * 2000-08-31 2005-06-28 Edwin Lundgren Control device for steering kite on a boat
US7030292B2 (en) * 2001-01-02 2006-04-18 Stemron, Inc. Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
US20030161817A1 (en) * 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US7250255B2 (en) * 2001-05-31 2007-07-31 Shinya Yamanaka Genes with ES cell-specific expression
US20040137460A1 (en) * 2001-05-31 2004-07-15 Shinya Yamanaka Genes with es cell-specific expression
US20080076176A1 (en) * 2001-08-27 2008-03-27 Advanced Cell Technology, Inc. De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
US20030044976A1 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
US20050079606A1 (en) * 2001-09-20 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. Pluripotent stem cells originating in skeletal muscle intestinal tissue
US20080003560A1 (en) * 2001-09-21 2008-01-03 Reprocell Inc. Tailor-made pluripotent stem cell and use of the same
US20050130144A1 (en) * 2001-09-21 2005-06-16 Norio Nakatsuji Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
US20080206865A1 (en) * 2001-10-03 2008-08-28 Su-Chun Zhang Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
US20060084172A1 (en) * 2001-12-10 2006-04-20 Julius-Maximilians-Unversitat Wurzburg Method for producing stem cells with increased developmental potential
US20050026133A1 (en) * 2002-01-31 2005-02-03 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
US20040048297A1 (en) * 2002-07-30 2004-03-11 Gene Logic, Inc. Nucleic acid detection assay control genes
US20070053884A1 (en) * 2003-05-16 2007-03-08 Kyowa Hakko Kogyo Co., Ltd Novel adult tissue-derived stem cell and use thereof
US20050019801A1 (en) * 2003-06-04 2005-01-27 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
US20100221827A1 (en) * 2003-11-26 2010-09-02 Rudolf Jaenisch Methods for reprogramming somatic cells
US20100144031A1 (en) * 2003-11-26 2010-06-10 Rudolf Jaenisch Methods for reprogramming somatic cells
US20050110830A1 (en) * 2003-11-26 2005-05-26 Masayuki Tashiro Ejection device, manufacturing device of color filter substrate, manufacturing device of electro-luminescent display device, manufacturing device of plasma display device, and ejection method
US20070155013A1 (en) * 2004-03-23 2007-07-05 Toshihiro Akaike Pluripotent stem cell growing method
US20080171358A1 (en) * 2004-06-01 2008-07-17 Jacques Perrault Expression System
US20070202592A1 (en) * 2004-07-08 2007-08-30 Yasuo Kitagawa Pluripotent Cells Distributed Ubiquitously In Animal Tissue, Which Proliferate Selectively In Lower-Serum Culture
US20060088599A1 (en) * 2004-08-02 2006-04-27 Prasad Paras N Amino functionalized ORMOSIL nanoparticles as delivery vehicles
US20060095319A1 (en) * 2004-10-29 2006-05-04 Cardwell Carlzo B Marketing and compensation method
US20080085555A1 (en) * 2005-02-28 2008-04-10 Takayuki Asahara Method For In Vitro Amplification Of Adult Stem Cells
US20070033061A1 (en) * 2005-04-05 2007-02-08 Achaogen, Inc. Business methods for commercializing antimicrobial and cytotoxic compounds
US20090047263A1 (en) * 2005-12-13 2009-02-19 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20090068742A1 (en) * 2005-12-13 2009-03-12 Shinya Yamanaka Nuclear Reprogramming Factor
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20100216236A1 (en) * 2005-12-13 2010-08-26 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20100210014A1 (en) * 2005-12-13 2010-08-19 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20100062533A1 (en) * 2005-12-13 2010-03-11 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20080132803A1 (en) * 2006-11-30 2008-06-05 Hyman Friedlander Method and system for doing business by mining the placental-chord complex
US20080171385A1 (en) * 2007-01-17 2008-07-17 Veit Bergendahl Culture of stem cells
US20080233610A1 (en) * 2007-03-23 2008-09-25 Thomson James A Somatic cell reprogramming
US20100184051A1 (en) * 2007-05-30 2010-07-22 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
US20090191159A1 (en) * 2007-06-15 2009-07-30 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US20100105100A1 (en) * 2007-06-15 2010-04-29 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US20100120069A1 (en) * 2007-06-15 2010-05-13 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US20100240090A1 (en) * 2007-06-15 2010-09-23 Izumi Bio, Inc. Methods and platforms for drug discovery
US20100267135A1 (en) * 2007-06-15 2010-10-21 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US20100075421A1 (en) * 2007-12-10 2010-03-25 Kyoto University Efficient method for nuclear reprogramming
US20090191171A1 (en) * 2008-01-18 2009-07-30 Yupo Ma Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous Recombination
US20100233804A1 (en) * 2008-03-17 2010-09-16 The Scripps Research Institute Generation of pluripotent stem cells using recombinant proteins
US20100093090A1 (en) * 2008-04-03 2010-04-15 Peking University Method and kit for efficient reprogramming of somatic cells
US20100021437A1 (en) * 2008-04-07 2010-01-28 The McLean Hospital Corporation Whitehead Institute for Biomedical Research Neural stem cells derived from induced pluripotent stem cells
US20100003757A1 (en) * 2008-06-04 2010-01-07 Amanda Mack Methods for the production of ips cells using non-viral approach
US20100062534A1 (en) * 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
US20100184227A1 (en) * 2008-10-24 2010-07-22 James Thomson Pluripotent stem cells obtained by non-viral reprogramming

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Mimeault et al. Concise Review: Recent Advances on the Significance of Stem Cells in Tissue Regeneration and Cancer Therapies. Stem Cells, 2006, Vol. 24, pp. 2319-2345. *
Takahashi et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006, Vol. 126, pp. 663-676. *
Yamanaka et al. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif. 2008, Vol. 41(Suppl. 1), pp. 51-56. *

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11512283B2 (en) 2005-08-29 2022-11-29 Technion Research & Development Foundation Limited Media for culturing stem cells
US9404079B2 (en) 2005-08-29 2016-08-02 Technion Research & Development Foundation Limited Media for culturing stem cells
US10385312B2 (en) 2005-08-29 2019-08-20 Technion Research & Development Foundation Limited Media for culturing stem cells
US20100062533A1 (en) * 2005-12-13 2010-03-11 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20090068742A1 (en) * 2005-12-13 2009-03-12 Shinya Yamanaka Nuclear Reprogramming Factor
US20090047263A1 (en) * 2005-12-13 2009-02-19 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8058065B2 (en) 2005-12-13 2011-11-15 Kyoto University Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells
US20100210014A1 (en) * 2005-12-13 2010-08-19 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US20100216236A1 (en) * 2005-12-13 2010-08-26 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US10968427B2 (en) 2006-08-02 2021-04-06 Teehnion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
US9834749B2 (en) 2006-08-02 2017-12-05 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
US9040297B2 (en) 2006-08-02 2015-05-26 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
US12060575B2 (en) 2006-08-02 2024-08-13 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
US20100120069A1 (en) * 2007-06-15 2010-05-13 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US20090191159A1 (en) * 2007-06-15 2009-07-30 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US20090299763A1 (en) * 2007-06-15 2009-12-03 Izumi Bio, Inc. Methods of cell-based technologies
US20100240090A1 (en) * 2007-06-15 2010-09-23 Izumi Bio, Inc. Methods and platforms for drug discovery
US20100105100A1 (en) * 2007-06-15 2010-04-29 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US8211697B2 (en) 2007-06-15 2012-07-03 Kyoto University Induced pluripotent stem cells produced using reprogramming factors and a rho kinase inhibitor or a histone deacetylase inhibitor
US8257941B2 (en) 2007-06-15 2012-09-04 Kyoto University Methods and platforms for drug discovery using induced pluripotent stem cells
US20100267135A1 (en) * 2007-06-15 2010-10-21 Kazuhiro Sakurada Multipotent/pluripotent cells and methods
US9714433B2 (en) 2007-06-15 2017-07-25 Kyoto University Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue
US20090324559A1 (en) * 2007-06-15 2009-12-31 Izumi Bio, Inc. Methods and platforms for drug discovery
US20090304646A1 (en) * 2007-06-15 2009-12-10 Kazuhiro Sakurada Multipotent/Pluripotent Cells and Methods
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US9540615B2 (en) 2008-03-17 2017-01-10 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US9771563B2 (en) 2008-03-17 2017-09-26 The Scripps Research Institute Chemical approaches for generation of induced pluripotent stem cells
US9068170B2 (en) 2008-03-17 2015-06-30 The Scripps Research Institute Generation of pluripotent stem cells using recombinant proteins
US20100267141A1 (en) * 2008-03-17 2010-10-21 The Scripps Research Institute Chemical approaches for generation of induced pluripotent stem cells
US20100233804A1 (en) * 2008-03-17 2010-09-16 The Scripps Research Institute Generation of pluripotent stem cells using recombinant proteins
US9394524B2 (en) 2008-03-17 2016-07-19 The Scripps Research Institute Chemical approaches for generation of induced pluripotent stem cells
US9926533B2 (en) 2008-03-17 2018-03-27 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US9534205B2 (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US20110110899A1 (en) * 2008-03-17 2011-05-12 Scripps Research Institute Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells
US20100279404A1 (en) * 2008-05-02 2010-11-04 Shinya Yamanaka Method of nuclear reprogramming
US9499797B2 (en) 2008-05-02 2016-11-22 Kyoto University Method of making induced pluripotent stem cells
US8906677B2 (en) 2008-12-17 2014-12-09 The Scripps Research Institute Generation and maintenance of stem cells
US9695395B2 (en) 2008-12-17 2017-07-04 The Scripps Research Institute Generation and maintenance of stem cells
US12054741B2 (en) 2008-12-17 2024-08-06 The Scripps Research Institute Generation and maintenance of stem cells
US20110044961A1 (en) * 2009-06-19 2011-02-24 Salk Institute For Biological Studies Generation of Induced Pluripotent Stem Cells from Cord Blood
US9909105B2 (en) 2009-10-16 2018-03-06 The Scripps Research Institute Induction of pluripotent cells
US9005968B2 (en) 2009-10-16 2015-04-14 The Scripps Research Institute Induction of pluripotent cells
US11046933B2 (en) 2009-10-16 2021-06-29 The Scripps Research Institute Induction of pluripotent cells
US9018010B2 (en) 2009-11-12 2015-04-28 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US10876094B2 (en) 2009-11-12 2020-12-29 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US10738281B2 (en) 2010-03-31 2020-08-11 The Scripps Research Institute Reprogramming cells
US9657274B2 (en) 2010-03-31 2017-05-23 The Scripps Research Institute Reprogramming cells
US9315779B2 (en) 2010-03-31 2016-04-19 The Scripps Research Institute Reprogramming cells
US10214729B2 (en) 2010-03-31 2019-02-26 The Scripps Research Institute Reprogramming cells
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US11305035B2 (en) 2010-05-14 2022-04-19 Musculoskeletal Transplant Foundatiaon Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10934528B2 (en) 2010-06-14 2021-03-02 The Scripps Research Institute Reprogramming of cells to a new fate
US9556417B2 (en) 2010-06-14 2017-01-31 The Scripps Research Institute Reprogramming of cells to a new fate
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
US10308912B2 (en) 2010-06-14 2019-06-04 The Scripps Research Institute Reprogramming of cells to a new fate
US9732319B2 (en) 2010-12-22 2017-08-15 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
US10844356B2 (en) 2010-12-22 2020-11-24 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
US11779610B2 (en) 2013-07-30 2023-10-10 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for using same
US10092600B2 (en) 2013-07-30 2018-10-09 Musculoskeletal Transplant Foundation Method of preparing an adipose tissue derived matrix
US11191788B2 (en) 2013-07-30 2021-12-07 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US10596201B2 (en) 2013-07-30 2020-03-24 Musculoskeletal Transplant Foundation Delipidated, decellularized adipose tissue matrix
US11268069B2 (en) 2014-03-04 2022-03-08 Fate Therapeutics, Inc. Reprogramming methods and cell culture platforms
US11596517B2 (en) 2015-05-21 2023-03-07 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US11524093B2 (en) 2015-07-24 2022-12-13 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11806443B2 (en) 2015-08-19 2023-11-07 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11938245B2 (en) 2015-08-19 2024-03-26 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
US11473083B2 (en) 2015-12-21 2022-10-18 Novartis Ag Compositions and methods for decreasing tau expression
WO2019165320A1 (en) * 2018-02-22 2019-08-29 Celularity, Inc. Post partum tissue-derived induced pluripotent stem cells and uses thereof

Also Published As

Publication number Publication date
GB2450603B (en) 2010-02-10
GB2465291A (en) 2010-05-19
US8257941B2 (en) 2012-09-04
JP5547064B2 (ja) 2014-07-09
WO2009006930A1 (en) 2009-01-15
US9714433B2 (en) 2017-07-25
WO2009007852A2 (en) 2009-01-15
US20090304646A1 (en) 2009-12-10
EP2171045B1 (en) 2016-12-21
AU2008273817A1 (en) 2009-01-15
IL202678A (en) 2015-09-24
EP2164952B1 (en) 2016-10-26
KR101657318B1 (ko) 2016-09-13
JP2010529851A (ja) 2010-09-02
US20090191159A1 (en) 2009-07-30
CN102317448A (zh) 2012-01-11
CN102317448B (zh) 2014-11-12
MX2009013706A (es) 2010-07-02
NZ582018A (en) 2012-05-25
GB2450603A (en) 2008-12-31
GB0922013D0 (en) 2010-02-03
IL202678A0 (en) 2011-08-01
US20100105100A1 (en) 2010-04-29
CA2690629A1 (en) 2009-01-15
HK1143831A1 (en) 2011-01-14
GB2465291B (en) 2012-01-18
JP2008307007A (ja) 2008-12-25
US8211697B2 (en) 2012-07-03
US20100240090A1 (en) 2010-09-23
EP2164952A1 (en) 2010-03-24
GB0810897D0 (en) 2008-07-23
WO2009006997A1 (en) 2009-01-15
US20100267135A1 (en) 2010-10-21
ZA200908904B (en) 2010-09-29
US20140206083A1 (en) 2014-07-24
EP2476749A1 (en) 2012-07-18
EP2171045A2 (en) 2010-04-07
AU2008273817B2 (en) 2013-10-24
US20090324559A1 (en) 2009-12-31
US20100120069A1 (en) 2010-05-13
KR20100059781A (ko) 2010-06-04
EP2213727A1 (en) 2010-08-04
AP2010005102A0 (en) 2010-02-28
WO2009007852A3 (en) 2009-08-20
MY159971A (en) 2017-02-15

Similar Documents

Publication Publication Date Title
US9714433B2 (en) Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue
JP6708617B2 (ja) 再プログラム化多能性細胞の作製
JP5553178B2 (ja) 効率的な人工多能性幹細胞の樹立方法
WO2009114949A1 (en) Methods for deprogramming somatic cells and uses thereof
US20150184131A1 (en) Enhanced Efficiency of Induced Pluripotent Stem Cell Generation
US20130065814A1 (en) Inductive production of pluripotent stem cells using synthetic transcription factors
JP2013535966A (ja) 引き抜かれた毛包由来のケラチン生成細胞から誘導多能性幹細胞を生成させる方法
EP2794856A1 (en) Induced pluripotent stem cells prepared from human kidney-derived cells
EP2501803B1 (en) Methods of enhancing pluripotentcy
JP6128511B2 (ja) ｉＰＳ細胞の高効率な樹立方法
KR20100097969A (ko) 인간 대동맥 평활근 세포로부터 제조된 유도성 전능 줄기세포
ngel Raya et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells
Rodríguez Pizà et al. Disease-corrected haematopoietic progenitors from Fanconi anemia induced pluripotent stem cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: IZUMI BIO, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER SCHERING PHARMA AKTIENGESELLSCHAFT;REEL/FRAME:022436/0471

Effective date: 20081209

AS Assignment

Owner name: KYOTO UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IPIERIAN, INC.;REEL/FRAME:025914/0102

Effective date: 20110127

AS Assignment

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER YAKUHIN, LTD.;REEL/FRAME:026112/0527

Effective date: 20071119

Owner name: IPIERIAN, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:IZUMI BIO, INC.;REEL/FRAME:026121/0942

Effective date: 20090701

Owner name: BAYER YAKUHIN, LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAKURADA, KAZUHIRO;ISHIKAWA, TETSUYA;MASAKI, HIDEKI;AND OTHERS;REEL/FRAME:026111/0124

Effective date: 20071115

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION